



CELEBRATING
25 Years of
Excellence

**NEW JERSEY
COMMISSION ON
CANCER
RESEARCH**

*Returning \$10 to
New Jersey for
Every Research \$1
Awarded*



2008 ANNUAL REPORT



New Jersey Commission on Cancer Research

Results Through Research

Celebrating its 25th anniversary in 2008, the New Jersey Commission on Cancer Research (NJCCR) strives to ensure that the citizens of New Jersey receive the fullest benefit of our nation's fight against cancer through the promotion and funding of research into the causes, prevention, and treatment of cancer.

Since 1983, the NJCCR has:

- ❖ leveraged over \$350 million back to New Jersey in national research awards.
- ❖ awarded over \$33 million for over 760 New Jersey cancer research studies.
- ❖ provided \$10 million for over 420 New Jersey students for training in cancer research laboratories.
- ❖ conducted over 50 conferences, educating over 12,000 cancer professionals and patients.
- ❖ reached over 120,000 cancer patients with our free *Resource Book for Cancer Patients in New Jersey*.



Dear Governor Corzine:

It is with a sense of great pride and accomplishment that the New Jersey Commission on Cancer Research (NJCCR) celebrates its twenty-fifth anniversary. Throughout its history, the NJCCR has sought to unite with members of the cancer community, so that we might work together to bring New Jersey to the cutting edge in the fight against cancer - and keep it there. As we look back, we can all be proud of the accomplishments that have been made.

Since 1983, the NJCCR's activities have been characterized by the demand for scientific excellence in research design, the expectation of the highest standards of outcomes and the insistence on the equitable treatment of all its constituents. Our major activity during these twenty-five years has been the underwriting of research grants to eligible nonprofit institutions throughout the state, and of cancer training fellowships for graduate students, postdoctoral fellows, and summer interns. This dedication to scientific excellence aimed at improving the health of our citizens, has been a source of great pride over the past 25 years.

Of course, there are also several noteworthy achievements and special recognitions that serve to confirm our value to the state and its citizens. One of these occurred in 1989, when the NJCCR was cited as a model for all states by the President's Cancer Advisory Board. As a result, a number of other states including Arizona, Colorado and Florida, have adopted similar programs. In 1995, another special achievement was the signing into law of the New Jersey Breast Cancer Research Fund, which dedicates funds by the inclusion of a check-off box on the state's income tax form. An additional milestone was reached when the New Jersey Conquer Cancer License Plate was created in 1997, comprising the first specialty license plate dedicated to cancer research in the country. Yet another highpoint occurred in 1999 when the NJCCR, along with a group of dedicated health care specialists, reached a *first of its kind* agreement with the major health care insurers in New Jersey. Through this historic health care breakthrough, NJ health insurers agreed voluntarily to pay for routine care in all phases of cancer clinical trials without legal and regulatory mandates. Finally, the value of the NJCCR's investment in research grants and training was confirmed unequivocally in 2007 when an intensive and independent evaluation of our program proved that such investments pay tremendous dividends. This evaluation found that our NJCCR-funded cancer researchers' leverage over \$10 back to NJ laboratories for every state dollar awarded, with more than \$350 million in research dollars returned to New Jersey laboratories over the years.

While we acknowledge the significant progress that New Jersey has made in the war on cancer, we must not forget that cancer still takes an enormous toll on our citizens. Therefore, much remains to be done as we look to the next twenty-five years. With this in mind, the NJCCR will continue to support strong basic science through its grant and fellowship programs, assure access to the most advanced clinical care by increasing opportunities to participate in clinical trials, enhance the quality of life of cancer patients, fight to reduce the burden that cancer holds for our underserved populations, and strive to educate patients, their families, and the public at large about new developments in cancer research.


The success of the past twenty-five years has come about through an unrelenting determination to conquer cancer, even in the face of an economic crisis and set backs. We understand the challenges that await us in the next phase of the campaign, which will call for uncommon singleness of purpose, courage, and generosity of spirit. These are the lessons of the NJCCR's past twenty-five years of remarkable success. They are also conditions for future success as we go forward, steadfast in our knowledge of the critical importance of basic research and with constant concern for the well being of the citizens of New Jersey. To this end, we can find inspiration in our achievements of the past twenty-five years, and we thank you and Commissioner Heather Howard, Department of Health and Senior Services for your continued support of our mission.

Sincerely,

A handwritten signature in blue ink that reads "Anna Marie Skalka". The signature is fluid and cursive, with a long, sweeping underline.

Anna Marie Skalka, Ph.D.
Chairwoman

A Message from the Chair



Section I: A 25 Year Review 2

Introduction 3

- ◆ History
- ◆ Mission
- ◆ Why State Cancer Funding Matters
- ◆ Serving New Jersey’s Citizens

NJCCR Milestones 8

Grants: 1983 – 2008 13

Fellowships: 1988 – 2008 25

Commission Members: Past & Present 38

Advisory Group Members: Past & Present 39

Section II: 2008 Annual Report 48

NJCCR Members and Staff 49

The Year’s Highlights 55

Research and Grant Highlights 59

Fellowships: A Commitment to the Future 61

Financial Summary 63

Celebrating the Life of Peter Doherty 65

ACKNOWLEDGEMENT

It is evident that the progress and achievements detailed in this report were realized through the vision, dedication and hard work of many individuals, particularly Commissioner Heather Howard, Deputy Commissioner Dr. Susan M. Walsh and State Epidemiologist Dr. Christina G. Tan of the New Jersey Department of Health & Senior Services.

The NJCCR is established in, but not of, the New Jersey Department of Health and Senior Services (DHSS). The NJCCR collaborates with the Office of Cancer Epidemiology Services, the Office of Cancer Prevention & Control, and the New Jersey Cancer Education and Early Detection program to offer integrated services to the citizens of New Jersey.

The NJCCR also benefits from the strong support services available in the DHSS, including fiscal, human resources, and information technology. The NJCCR works effectively with the DHSS to implement its mission of service to the public.

CELEBRATING
25 Years of
Excellence

Section 1: A 25 Year Review





The New Jersey Commission on Cancer Research (NJCCR) promotes significant and original research into the causes, prevention and treatment of cancer and serves as a resource to providers and consumers of cancer services.

HISTORY

It is difficult to find anyone in New Jersey who has not been touched in some way by cancer. Our state consistently ranks among the top ten in the nation in cancer morbidity and mortality. The cost of this disease is measured in human suffering, in lives lost, potential wasted and huge medical care expenses. According to 2008 American Cancer Society estimates, 45,900 people in New Jersey were diagnosed with cancer and over 16,800 succumbed to the disease.

Prior to 1983, New Jersey did not have a comprehensive public health plan to address the burden of cancer and the toll it was taking on its citizens. Because of this health care burden, in 1983 the New Jersey legislature created the New Jersey Commission on Cancer Research. With the creation of the NJCCR the legislature established an ongoing (although declining) source of funds from the state's tobacco tax to support significant cancer research projects by New Jersey scientists. For the past 25 years, the NJCCR has provided more than \$33 million to New Jersey's non profit research institutions for discovery-oriented cancer research.

MISSION

Since 1983, the goal of the NJCCR has been to fund promising cancer research from New Jersey's most creative scientists. Early on, we recognized that the only sure strategy for success, given our modest funding abilities, was to invest in the most talented people. Using a National Institutes of Health system of scientific merit review, the NJCCR supports emerging, talented researchers embarking into the competitive world of cancer research. The NJCCR also supports established investigators embarking on new research directions.

This support provides critical leverage in developing new scientific infrastructure as well as expanding existing assets and networks crucial for a broad-based, comprehensive approach to solving the problem of cancer in New Jersey.

WHY STATE CANCER FUNDING MATTERS

New Jersey currently faces an economic crisis unprecedented in the history of the state. Why should its citizens continue to fund cancer research during such difficult times?

Benefits of Supporting Research

- *Strengthens NJ's capacity for innovation*
- *Attracts and retains highly skilled research personnel*
- *Trains students for academic, pharmaceutical and biotech industries*
- *Promotes networking, collaboration, and multidisciplinary work among researchers*

For an increasing number of people, a diagnosis of cancer is no longer a death sentence. In recent years, statistics have shown that the death toll from some of the most common cancers has dropped to its lowest levels, survival rates continue to climb, and more specifically, more than three quarters of children with cancer survive. These outcomes have been possible thanks in no small part to the efforts of the thousands of cancer researchers and doctors who have dedicated their lives to beating this disease. Scientific research into cancer does make a difference – and New Jersey is proud to be leading the way in the fight.

In addition, university-based research strengthens the recipient institutions. World-class research institutions such as Rutgers, Princeton and the University of Medicine and Dentistry of New Jersey attract highly talented students and faculty. Healthy growing academic institutions bolster New Jersey's economy.

New Jersey's cancer research enterprise extends beyond the laboratory and campus. NJCCR research funding augments New Jersey's reputation as 'the world's medicine chest.' Our state has one of the highest concentrations of pharmaceutical and biotechnology industries in the country; a \$25 billion "engine of growth." The ability of these industries to tap New Jersey's cancer research talent as well as its research breakthroughs bolsters their strength and in turn New Jersey's economy.

As previously stated, NJCCR has provided more than \$33 million in discovery-oriented cancer research grants in its 25-year history. NJCCR research grant recipients have, in turn, brought to New Jersey research laboratories millions of dollars in federal financial support. A recent independent evaluation of the NJCCR by the Edward J. Bloustein School of Public Policy at Rutgers has shown that the NJCCR represents one of New Jersey's great success stories in terms of public investment in cancer research.

Facts:

- **25% of New Jersey's pharmaceutical company employment costs are devoted to research and development.¹**
- **The economic impact of New Jersey's pharmaceutical industry and medical technology industries was over \$27 billion in 2007.²**
- **In 2006 New Jersey experienced a 22.2% growth in the number of drug and pharmaceutical establishments.³**

1 HealthCare Institute of New Jersey, Economic Study titled "2008 Annual Report"

2 Ibid

3 Battelle "Technology, Talent and Capital: State Bioscience Initiatives – 2008"

- In 2006 New Jersey experienced 6.4% growth in employment in the pharmaceutical industry.⁴
- New Jersey is home to over 410,000 scientists and engineers.⁵
- New Jersey ranks 7th in the nation in number of doctoral scientists, reflecting the state's thriving intellectual community.⁶

SERVING NEW JERSEY'S CITIZENS

Cancer is one of the number one health concerns of the citizens of New Jersey. The NJCCR has a long history of innovative programs and educational initiatives aimed at community outreach and research dissemination. Together with its advisory groups and community partners, the NJCCR has worked to mobilize, integrate and coordinate the delivery of research discovery and cancer interventions to all New Jersey citizens. Examples of groundbreaking NJCCR programs are as follows:

IMPACT NEW JERSEY

(IMPROVING MINORITY AND MEDICALLY UNDERSERVED PARTICIPATION AND ACCESS TO CANCER CLINICAL TRIALS)

Participation in cancer clinical trials (CCTs) is low for many minorities and underserved populations. Misperceptions, inaccurate beliefs, and myths about clinical trials are common barriers, yet few actual interventions exist to reduce these obstacles.

In 2001, the NJCCR joined with the 100 Black Men of New Jersey to address the low participation of ethnic minorities in cancer clinical trials. The result was the formation of a new program, called IMACT NJ, representing a partnership that includes community leaders, researchers, healthcare providers and faith based groups. Created to reduce barriers to enrollment in CCTs, IMPACT NEW JERSEY's goals are to develop and launch a community-based education program aimed at increasing knowledge and understanding of the CCT process, engaging consensus building to address barriers, and promoting self-advocacy.

⁴ Ibid


⁵ New Jersey Department of Labor and Workforce Development, May 2006

⁶ National Science Foundation/Division of Science Statistics

A RESOURCE BOOK FOR CANCER PATIENTS IN NEW JERSEY

Helping patients deal with the complexities of cancer, find critical resources and learn self advocacy.

Originally published in 1991 by the NJCCR's Joint Nursing and Psychosocial Advisory Group, the resource book provides anyone facing cancer with critical information and guidance from the day of diagnosis to long term survivorship. Over 120,000 books have been distributed to date through oncology offices, cancer organizations, local legislative offices or by the NJCCR. The book has been updated four times and receives wide spread accolades from patients and health providers alike.



TAKING AIM AT IMPROVING QUALITY OF LIFE FOR CANCER PATIENTS

As survival has improved for cancer patients, significant concerns have been raised about the effects of cancer and its treatment on the quality of a cancer patient's life. The choices facing patients and families are considerably more complex today and require timely and comprehensive information about both the benefits and the physical, emotional and financial toll of treatment. The challenges and opportunities presented by quality of life issues were the driving force that led the NJCCR's Psychosocial/Nursing Advisory Group to design and conduct a "roundtable" discussion on moving New Jersey forward in Quality of Life. A report including policy issues and considerations may be found at www.njccr.com.

SHARING PERSPECTIVES: RESEARCHERS REACHING OUT

Educating cancer patients, survivors and the public about emerging developments in cancer research has always been a high priority for the NJCCR. Designed by cancer patients for cancer patients, this program seeks to open channels of communication and encourage interaction between researchers and survivor/advocate communities. Highlights of cancer studies by New Jersey scientists are emphasized.



CANCER & THE OLDER ADULT

More than one-half of all new cancer diagnoses are in adults over the age of 65 and more than 70% of cancer deaths occur in this age group. Yet, very little attention has been paid to the needs of cancer and older adults. In order to strategically address this emerging concern, the NJCCR formed a Task Force on Cancer in the Older Adult. The task force promotes a statewide, comprehensive approach to this problem with a special focus on research and clinical trials, myths and misperceptions, co-morbidities and treatment decisions and screening/wellness. The group has been studying this issue for several years and will publish a strategic policy report in the very near future.

CANCER SURVIVORSHIP

More than 60% of people diagnosed with cancer now survive five years or more after treatment. Despite significant advances in cancer treatment and increased attention to general health, little is known about the level of wellness experienced by these survivors. In fact, many survivors who anticipated a return to pre-morbid health find themselves experiencing ongoing and distressing health and psychosocial sequelae problems. As a result, the Joint Nursing/Psychosocial Advisory Group to the NJCCR sponsored a series of national conferences for researchers and health providers to bring attention to this important concern. Reports on these activities can be found at www.njccr.com.

BREAST and PROSTATE CANCER RESEARCH FUNDS

In 1995, the New Jersey Breast Cancer Research Fund was established and fueled through individual contributions from a check off box on the New Jersey State Income tax form. Since that time, over 195,000 donations have been received, averaging \$235,000 per year. In 2005, a New Jersey Prostate Cancer Research Fund was created and efforts to expand the reach of that fund are under development. One hundred percent of donations to the fund are awarded in competitive grants to talented breast and prostate cancer scientists.

1984

1982

The Cancer Research Act (S390) was introduced in the New Jersey Senate by the late Senator Walter Rand, pictured here with Governor Thomas Kean.



Mr. John J. Fay, Jr. is hired as the NJCCR's first executive director. Ms. Ann Marie Hill is hired as the scientific administrative assistant. The first 15 cancer research grants are awarded to NJ scientists..



1986

Based upon recommendations made at the "Working Conference on Cancer Research" five permanent advisory groups are created: Basic Research, Clinical Multidisciplinary Research, Pediatric Oncology, Psychosocial/Nursing Group, and Radiation Oncology.

1988

Ten predoctoral and eleven postdoctoral students receive the first New Jersey Cancer Research Fellowship awards. Two programs are established, The Cooperative Oncology Group of New Jersey and the New Jersey Cancer Research Development Program, which earmarked funds for special cancer topics of significant concern to the citizens of New Jersey.

Milestones of the New Jersey C

1983

Governor Thomas H. Kean signs the Cancer Research Act establishing the New Jersey Commission on Cancer Research (NJCCR). Dr. Herbert E. Spiegel is appointed chair.




1985

First of its kind, statewide "Working Conference on Cancer Research" held. Co-sponsored by Senator Frank R. Lautenberg, 136 scientists attend this conference to launch a cooperative effort to identify, prioritize and evaluate cancer research needs in New Jersey.



1987

Dr. Frederick B. Cohen is elected chair of the NJCCR. The first cancer research symposium in New Jersey entitled "New Frontiers in Cancer Research" is held; over 300 scientists and physicians attend.



1990

A select group of dedicated students receive the first NJCCR Summer Fellowship Awards. Members of the NJCCR create a strategic plan to enhance New Jersey's competitive edge for the procurement of federal cancer research funds.



1994

Breast Cancer Advocates Judi Mason Klein and Joyce Maso campaign former Assemblywoman Rose Heck (R-28) and former Assemblyman Chuck Haytaian (R-23) to introduce bill A1701 to establish the New Jersey Breast Cancer Research Fund. The fund allows taxpayers to voluntarily contribute a portion of their income tax to breast cancer research in New Jersey.



1992

A Resource Book for Cancer Patients, which provides important information for cancer patients on services and programs available in New Jersey, is published.



Commission on Cancer Research

1989

National Cancer Advisory Board recognized the NJCCR as a national model in its report "Fighting Cancer in America." This honor was further enhanced when the Journal of the National Cancer Institute highlighted the NJCCR's accomplishments in its December 6, 1989 issue. Mr. John J. Fay Jr. retires and Ms. Ann Marie Hill is appointed as the NJCCR's second executive director.



1991

NJCCR provides assistance to new investigators by co-sponsoring the "Workshop for Successful Grant Writing."

1993

NJCCR initiates a series of public forums designed to allow professionals and the public to express their ideas on the value, need and direction of cancer research in New Jersey.




1995

Governor Christine Todd Whitman signs the New Jersey Breast Cancer Research Fund into law. Longstanding members of the NJCCR; Drs. Herbert Spiegel, Robert Tucker, William Parker, James Orsini and Zola Horovitz retire. *A Resource Book for Cancer Patients* in New Jersey is made available in Spanish.



1996

Governor Christine Todd Whitman signs The Genetic Privacy Act. The NJCCR joins forces with the Cancer Institute of New Jersey to jointly sponsor the *Annual Retreat on Cancer Research in New Jersey*.



1998

A report entitled "Prostate Cancer in New Jersey: A Time for Action" was prepared by the NJCCR on behalf of New Jersey's health care professionals, community leaders and cancer survivors. NJCCR staff participates in the "The March: Coming Together to Conquer Cancer" in Washington, D.C.



2000

Governor James E. McGreevey signs P.L. 2000, C. 63 (C.52:9u-5) requiring the NJCCR to take steps necessary to encourage the development of research projects on pain management and palliative care for persons diagnosed with cancer in New Jersey. Dr. Paul Wallner is elected chair of the NJCCR. The NJCCR co-sponsors its second national conference entitled "Cancer Survivorship Throughout the Lifespan: Challenges for the 21st Century."



Milestones of the New Jersey C

1997

The NJCCR takes its fight against cancer to the streets through a specialty "Conquer Cancer" license plate. It is the first license plate in the country to raise funds for cancer research and was developed through the tireless efforts of the late Mr. Peter Doherty.



1999

The NJCCR, along with Governor Whitman and a group of dedicated health care specialists, reach a first of its kind agreement with major health care insurers in New Jersey. Through this historic agreement, NJ health insurers agree to voluntarily pay for routine care in all phases of cancer clinical trials.



2001

New Jersey artists joined forces with breast cancer experts to design a unique breast cancer calendar. Governor James E. McGreevey signs the New Jersey Prostate Cancer Research Fund into law allowing taxpayers to voluntarily contribute a portion of their income tax to prostate cancer research in New Jersey.



10.....Returning \$10 to New Jersey for Every Research \$1 Awarded

2004



Mr. Vincent Curatola, who portrayed the character of the New York mafia boss Johnny Sack on the HBO series, The Sopranos, graciously volunteers to help the NJCCR in its fight against cancer by taping several public service announcements. Dr. Anna Marie Skalka is elected chair of the NJCCR. Dr. Frederick B. Cohen is honored with the title of Emeritus Member to the NJCCR in recognition for his 20 years of extraordinary leadership and effort.



2002

The NJCCR sponsors three conferences; Sharing Perspectives on Biomedical Research, Demystifying Oncology Research: The Journey from Clinician to Educated Research Consumer and on to Investigator, and Cancer and Aging: A Call to Action.

2006

The NJCCR, along with Rider University, co-sponsor the conference "10 Years of The Breast Cancer Research Fund: A Celebration of Survivorship."



Commission on Cancer Research

2003

IMPACT NJ (Improving Minority & Medically Underserved Participation and Access to Clinical Trials) advisory group and program is launched to reduce the barriers to enrollment in clinical trials by addressing myths and building trust within communities.



2005

The NJCCR sponsors a professional education conference entitled "Fostering Wellness after Cancer" to explore the current research in survivors' wellness; the role of health care professionals in fostering and promoting quality of life for survivors; and the components of a compelling research agenda for New Jersey.


2007

Rutgers, The State University of New Jersey conducts a 15 month intensive and independent evaluation of the NJCCR programs. One of the most significant findings of the report proved that the NJCCR's open and fair system of grant awards leverages over \$10 in federal funds back to New Jersey for every state dollar awarded.



12.....*Returning \$10 to New Jersey for Every Research \$1 Awarded*

25 Year Grant Totals



CANCER INSTITUTE OF NEW JERSEY

Kim M. Hirshfield	Epithelial Integrity and Breast Cancer Recurrence	\$132,000	2008 – 2010
Roger Strair	A Pilot Study of Nuclear Factor kappa-B Inhibition	\$132,000	2008 – 2010
Isaac Yi Kim	BMP-6 and Neuroendocrine Differentiation in Prostate Cancer	\$52,800	2009 – 2009
Debabrata Banerjee	Bone Marrow Derived MSCs for Therapy of Liver Mets of CRC	\$48,675	2007 – 2008
Grace Lu-Yao	Testosterone Supplementation and Risk of Prostate Cancer	\$99,000	2006 – 2008
Lorna Rodriguez	Regulation of Multidrug Resistance by CD44	\$97,900	2006 – 2008
Kim Hirshfield	Clinical Impact of SNPs in the P53 Pathway	\$50,050	2006 – 2007
Debabrata Banerjee	Bone Marrow Derived Mesenchymal Stomal Cells for Therapy of Liver Mets of Colorectal Cancer	\$47,025	2005 – 2006
Dale Schaar	The Development of Phorbol Ester-Based Therapy for AML	\$49,500	2005 – 2006
John Glod	The Role of Endothelial-like Monocytic Cells in Angiogenesis in CNS Tumors	\$97,900	2004 – 2006
Stuart Lutzker	Mitotic Checkpoint Function and Cancer Cell Chemosensitivity	\$100,000	2003 – 2005
Roderich Schwarz	Targeting TGF-beta in Pancreatic Cancer	\$49,500	2003 – 2004
Linda Patrick-Miller	The Impact of a Relative's Mammogram: A Teachable Moment	\$34,249	2002 – 2003
Daniel J. Medina	Lymphoma Vaccine Development	\$100,000	2001 – 2003
Derek Taller	Differential Gene Profiling of C-Terminal p53 Mutants	\$33,000	2001 – 2003
Jan B. Wollack	Cerebral Folate Transport: Role in Cancer Treatment	\$97,900	2001 – 2003
Arvin Yang	Cytokine Optimization of Anti-Tumor Vaccines	\$33,000	2001 – 2003
David Gorski	The Growth Arrest-Specific Homeobox Gene Gax in Cancer	\$99,000	2000 – 2002

Grants: 1983 – 2008

Stuart Lutzker	Regulation of p53 Via the C-terminus	\$48,950	2000 – 2001
James Goydos	Using RT-PCR Analysis to Improve Melanoma Staging	\$48,969	2000 – 2001
Roger K. Strair	Adenovirus Cytotoxicity of Malignant Lymphoid Cells	\$88,000	1999 – 2001
Judith Bash	Molecular Determinants of Sensitivity to Antimitotic Drugs	\$58,050	1999 – 2001
Khew-Voon Chin	Analysis of Drug Resistance by DNA Microarray	\$44,000	1999 – 2000
Robert S. DiPaola	Characterization of Antitumor Molecules from Estrogenic Herbs	\$39,523	1999 – 2000
F. Joseph Germino	The CR2 Region of CyclinA: Its Involvement in ATL	\$34,210	1999 – 2000
Weng-Lang Yang	The Role of RI Subunit of PKA in Cell Growth Regulation	\$29,025	1998 – 1999
William Hait	The Role of Calmodulin - Dependent Protein Kinase III in Cellular Proliferation of Breast Cancer	\$50,000	1995 – 1997
William Hait	Apoptosis and Clinical Results in Non - Hodgkin's Lymphoma	\$42,550	1995 – 1996
T. S. Ravikuamar	Repository of Cancer Biomaterials for Research	\$99,719	1995 – 1996
K V Chin	Regulation of EGFR by PML in Breast Cancer	\$44,000	1994 – 1995

CENTER FOR ADVANCED BIOTECHNOLOGY & MEDICINE

Arnold Rabson	Role of NF-kB in Prostate Cancer	\$99,000	2000 - 2002
Beatrice Rayet	Functional Characterization of v-Rel in Oncogene	\$58,050	2000 - 2002
Cory Abate Shen	A Mouse Model of Prostate Cancer	\$75,000	1999 - 2001
Abram Gabriel	Role of DNA Repair Genes in Cancer-Causing Chromosomal Rearrangements	\$86,900	1999 - 2001
Rajula Bhatia-Guar	The Role of Nkx#.1 in Prostate Cancer	\$58,050	1999 – 2001
Fang Liu	Role of TGF-Beta-Inducible Gene Regulation in Tumorigenesis	\$44,000	1999 - 2000
Cory Abate Shen	Role of Pso - 1 in Normal Development and Prostate Cancer	\$53,348	1996 – 1997
Michael Shen	Oncogenic Role of a Novel EGF related Growth Factor	\$86,411	1995 – 1997
Arnold Rabson	Rearrangement of an NF - kB Gene in Human T-cell Leukemia	\$73,357	1993 – 1995

COOPER HEALTH SYSTEM

John P. McCoy	CD10, CD34, and Chromosome Aneuploidy in pediatric ALL	\$36,807	1997 – 1999
Intae Lee	Mechanisms of Infusional Brachytherapy in Solid Tumors	\$42,098	1995 – 1996
Jack Goldberg	New Jersey Network for Clinical Oncology Research	\$24,000	1994 – 1997
Michael Nunno	Radon Induced Genetic Damage in Lung Cancer	\$41,882	1988 – 1989

CORIELL INSTITUTE FOR MEDICAL RESEARCH

Rick Cohen	Purifying of Normal Stem Cells from Leukemic Patients	\$49,500	2004 - 2006
Dominique Bonnet	Determination of the Biological Properties of Human Acute Myeloid Leukemic Stem Cells Using the NOC/SCID Mouse Model	\$42,350	1999 - 2000
Gary Butler	Development of Mycoplasma Arginine	\$43,977	1992 – 1993
Gary Butler	Development of Arginine Deiminase	\$42,881	1991 – 1992
Chung H. Kim	Late SV40 Transcription Factor	\$85,808	1988 – 1990
Thomas Atherholt, PhD	In Vivo Effects of Low - Level Radiation	\$84,565	1986 – 1988
Arnold S. Dion	Molecular Studies of MuMTV	\$44,000	1985 – 1986
Gerard McGarrity	Improved Methodology in Water Evaluations	\$71,940	1985 – 1986

GARDEN STATE CANCER CENTER, BELLEVILLE

Jack Burton	Doxorubicin-Immunoconjugate Therapy of Lymphoma	\$99,000	2004 - 2006
Rosalyn Blumentahal	CEA-Directed Immunotherapy for Metastasis	\$96,200	2002 - 2004

Alice Taylor	Placental Growth Factor Regulation in Tumors after Cytotoxic Therapy	\$99,000	2001 - 2003
David M. Goldenberg	Modulation of Chemosensitivity by Sphingomyelin	\$99,000	2000 - 2002
David M. Goldenberg	Immunodiagnosis of Breast Cancer	\$50,000	1999 - 2000
Rita Alisaukas	Chronobiology of Experimental IL - 12 Immunotherapy	\$86,900	1998 – 2000
David Goldenberg	Advances in Biological Therapy of Cancer	\$38,500	1998 – 2000
David Goldenberg	Immunodiagnosis of Breast Cancer	\$50,000	1998 – 1999
Robert Sharkey	Avidin - Biotin Targeting of Colorectal Cancer	\$44,000	1993 – 1994
M. Jules Mattes	The Role of Complement as a Tumoricidal Mechanism	\$86,900	1992 – 1994
Julius Martin	Structural Requirements of c – myc	\$43,450	1991 – 1992
R. Blumenthal	Low Dose Rate Radiation	\$42,231	1991 – 1992
Akio Tanaka	Control of Oncogenic	\$84,040	1990 – 1992
Marc Monestier	Anti - Idiotype Antibodies	\$38,060	1990 – 1992
Rhona Stein	Targeting of Lung Cancer with Novel Monoclonal Antibodies	\$79,882	1990 – 1992
Charlene Williams	DNA Cloning and Expression of Breast	\$88,000	1989 – 1991
David. Goldenberg	Radioimmunodetection	\$12,500	1988 – 1990
David V. Gold	Immunobiology of Murine LAK	\$86,900	1988 – 1990
Arnold S. Dion	Breast Tumor Glycoconjugates	\$79,970	1987 – 1990
Lisa Beewen Shih	Synthesis of Immunotoxins for Tumor Therapy	\$78,333	1986 – 1988
David Goldenberg	A New Colorectal Cancer Marker	\$87,886	1985 – 1986

HACKENSACK UNIVERSITY MEDICAL CENTER

Gary Walco	Cancer Survivorship: Life Span Approaches for Research	\$36,000	1997 – 1999
Gary Walco	Psychosocial Support Groups in Childhood Cancer	\$30,000	1995 – 1997

MONMOUTH MEDICAL CENTER, LONG BRANCH

Barbara Rabinowitz	Psychosocial and Nursing Research Education Project	\$13,651	1993 – 1994
--------------------	---	----------	-------------

MONTCLAIR STATE UNIVERSITY

Elizabeth Clark	Establishing a Psychosocial Database	\$28,724	1990 – 1991
-----------------	--------------------------------------	----------	-------------

NEW JERSEY INSTITUTE OF TECHNOLOGY

Sam Sofer	Synthesis of Lipo - soluble Gd Lipos	\$2,750	1991 – 1991
Sam Sofer	Synthesis of Lipo - soluble Gd Lipos	\$19,470	1990 – 1991

PRINCETON UNIVERSITY

Humayra Ali	Optimization of an Adenoviral Vector for Cancer Therapy	\$40,000	2006 – 2008
Hillary Collier	Tissue Quiescence in Homeostasis and Breast Cancer	\$49,500	2007 – 2008
Hillary Collier	Tissue Quiescence in Homeostasis and Breast Cancer	\$49,500	2006 – 2008
Guohong Hu	Metastasis Regulatory Programs of Breast Cancer	\$70,500	2006 – 2008
Jane Phillips	The Role of Pif1p in Telomerase Inhibition	\$40,000	2006 – 2008
Yibin Kang	Genetic Basis of Breast Cancer Progression from Dormancy	\$97,900	2005 – 2007
Eain Murphy	Mutational Analysis of Recently Identified HCMV ORF's	\$69,000	2004 – 2006
Martha Klovstad	Meiotic DSB and Checkpoint Activation	\$38,000	2004 – 2005
Kathleen Daumer	The Role of Est3p at the Telomere	\$38,000	2004 – 2005
Daryl Gohl	Mechanisms of Bithorax Complex Boundary Function	\$38,000	2004 – 2005

Grants: 1983 – 2008

Courtney Williams	Role of Stromal Fibronectin in Breast Cell Oncogenesis	\$38,000	2004 – 2005
Rebecca Burdine	Analysis of the Zebrafish Cystic Kidney Mutant Switch Hitter	\$99,000	2004 – 2006
Brendan Rickards	Identification of Partners of Fra-1	\$33,000	2003 – 2005
Jean-Baptiste Boule	Functional Study of the Yeast Telomerase Heloenzyme	\$58,050	2003 – 2005
Katherine Clouse	Restricted Gene Expression of EGFR Ligands	\$33,000	2003 – 2005
Anders Lilja	Interaction of Cytomegalovirus with Tumor Cells	\$58,050	2003 – 2005
Mateusz Oprychal	Regulation of Stability of Proto-Oncogene mRNAs	\$33,000	2003 – 2005
Kui Huang	Regulation of Cell Adhesion in Human Cancer	\$58,050	2002 – 2004
Ali Nouri	APC Tumor Suppressor's Role in Cell Migration	\$33,000	2002 – 2004
Amy Cocina	Structural Analysis of Two C. elegans Apoptotic Proteins	\$33,000	2002 – 2004
Jeonghyeon Park	Chromatin Modifying Complexes in Myc Oncogenesis	\$58,050	2002 – 2004
Eric Shiozaki	Structural Analysis of Caspase-9 Regulation	\$33,000	2002 – 2004
Scott Steele	Analyses of a Putative Imprinting Control Region	\$33,000	2002 – 2004
Nicholas Tolwinski	Wnt Signaling and the Control of Cell Morphology	\$33,000	2002 – 2004
Datsen Wei	Murine NKT Cell Development	\$33,000	2002 – 2004
Susan Schweinsberg	Characterization of the Fab7 Boundary Element	\$33,000	2001 – 2003
Ekaterina Semenova	Analysis of The Embryonic Lethal Detection Mutant s-1Acrg	\$33,000	2001 – 2003
Dai Wang	Low-Molecular-Weight Proteins of Human Cytomegalovirus	\$58,050	2001 – 2003
Dina Matheos	The Role of Fus3p in Cell Fusion	\$33,000	2001 – 2003
Sanjay Chandriani	Interactions between Myc and Chromatin	\$33,000	2001 – 2003
Jessica B. Bessler	Telomeres and the Rrm3p Helicase	\$33,000	2001 – 2003
Mellisande R. Wolf	Orb in Translation and mRNA Localization in Oncogenesis	\$58,050	2001 – 2003
Ying Wang	Integration of Nutrient-Activating Signaling Pathways	\$58,050	2000 – 2002
Yigong Shi	Structural Studies of the Tumor Suppressor Proteins in TGF-B Signaling	\$81,400	1999 – 2001
Waheeda Khalfan	Genetic Analysis of the SPB Component Karlp in Yeast	\$33,000	1999 – 2001
Myeongwoo Lee	Characterization of Integrin Signalling in Vivo	\$58,050	1999 – 2001
Irena Ivanovska	Genetic Characterization of MTOC Duplication in Yeast	\$33,000	1998 – 2000
Micheal Cole	N - Myc Oncogene - Specific Nuclear Factor Interactions in Pediatric Cancer	\$88,139	1997 – 1998
Thomas Vogt	Role of the Fringe Genes in Mammary Development & Cancer	\$44,000	1997 – 1998
J. Schwarzbauer	Initiation of Fibronectin Matrix Assembly	\$44,000	1994 – 1995
Marilyn Resh	Activation of the c - mrc Proto – onco	\$81,400	1990 – 1992
S.J. Flint	In Vitro Studies of Regulation of cmyc	\$87,450	1989 – 1991
Iva S. Greenwald	Mutagenesis of EGF Homeotic	\$84,516	1987 – 1989
Ruth Steward	Oncogenes and Development	\$86,235	1987 – 1989
Timothy L. Manser	Tissue Specificity of Ca in T antigen	\$85,313	1986 – 1988
Thomas E. Shenk	Gene Product Responsible for Mammary	\$88,000	1985 – 1987
Michael D. Cole	Characterization of a Novel Oncogene	\$80,300	1985 – 1986

RICHARD STOCKTON COLLEGE OF NEW JERSEY

Mary Lou Galantino	Impact of Yoga on Chemotherapy in Women in Breast Cancer	\$49,493	2007 – 2008
--------------------	--	----------	-------------

RIDER UNIVERSITY

Julie Drawbridge	The C-ret Signaling System in Kidney Morphogenesis	\$87,365	1998 – 2000
Jonathan Yavelow	New Jersey Cancer Research Workshop	\$25,641	1992 – 1993

James Riggs	Role of Chronic Stimulation in B Cell Lymphomagenesis	\$83,848	1992 – 1994
Jonathan Yavelow	Protease Inhibitors	\$87,641	1987 – 1989
Jonathan Yavelow	Anticarcinogenic Mechanisms in Birk Protease Inhibitors	\$56,220	1986 – 1988

RUTGERS, THE STATE UNIVERSITY

Gyan V. Bhanot	RT-PCR Assay for Breast Cancer Subtypes	\$132,000	2008 – 2010
Anant Madabhushi	Computerized detection and grading of prostate cancer histology	\$66,000	2008 – 2009
Ruth Steward	PDCD2/Zfrp8 in Cell Proliferation and Leukemia	\$99,000	2007 – 2009
Guy Werlen	The Role of PEA-15 in T Lymphocyte Development and Activation	\$99,000	2007 – 2009
Dessislava Dimova	Genomic Study of CDK-independent Functions of Retinoblastoma Proteins	\$99,000	2006 – 2008
Hwa Jin Lee	Therapeutic Strategies for Melanoma	\$70,050	2006 – 2008
Vincent Shen	Regulation of mRNA Decay Pathways & Cancer	\$40,000	2006 – 2008
Mousumi Bose	EGCG and Omega-3 PUFA in Colon Cancer Prevention	\$38,000	2005 – 2007
Joseph Porter	Regulation of RNA Decay in Activated/Transformed B Cells	\$69,000	2005 – 2007
Mohamed Rafi	In Vivo Efficacy and Proteomics Study Using a New Anticancer Compound	\$25,630	2005 – 2006
Yao-Ping Lu	Selectivity of Proapoptotic Effects of Caffeine	\$49,500	2005 – 2006
Gutian Xiao	Role of the Prontoc-protein Cot in HTLV Tax-induced Tumors	\$99,000	2004 – 2006
Samuel Gunderson	Human Papillomavirus 16: Regulation of Polyadenylation	\$99,000	2004 – 2006
Mohamed Rafi	In Vivo Efficacy and Proteomics Study Using a New Anticancer Compound	\$45,000	2004 – 2005
Andrew Bush	The Role of Inflammation in a Mouse Model of Prostate Cancer	\$49,500	2004 – 2005
Khew-Voon Chin	Mechanisms of RI-alpha and RIAZ in Cell Growth Regulation	\$97,900	2003 – 2005
Kristina Lu	Analysis of a CD40 Related B Cell Proliferation Defect	\$33,000	2003 – 2005
Xi Zheng	TPA-Induced Apoptosis in Myeloid Leukemia Cells	\$99,000	2003 – 2005
Gabriella Alexe	Collective Biomarkers in Breast and Prostate Cancer	\$58,050	2003 – 2005
Garth Patterson	Functional Genomic Study of Breast Cancer-Related TGF-beta Target Genes	\$99,000	2003 – 2004
David E. Axelrod	Quantitative Histopathology of Breast Carcinoma In Situ	\$97,802	2002 – 2004
Longqin Hu	Novel Bifunctional Dendrimers Targeting Tumor Cells	\$96,000	2002 – 2004
Elise Lev	Prospective Study of Quality of Life of Men Receiving Brachytherapy for Prostate Cancer	\$46,900	2002 – 2003
Robert Major	Analysis of Notch Signaling in Organized Tissue Growth	\$33,000	2001 – 2003
Kevin Sweder	Role of the 26S Proteasome in Regulation of DNA Repair	\$99,000	2001 – 2003
Fang Liu	Role of Cyclin-Dependent Kinase Phosphorylation of SMAD	\$99,000	2001 – 2003
Longqin Hu	New Cyclophosphomides with Novel Activation Mechanisms	\$96,601	2000 – 2002
Cole Zimmerman	Cell Cycle Regulation by TGF Signaling in C. elegans	\$58,050	2000 – 2002
Marion Gordon	Emmprin, A Tumor Product Inducing Matrix Metalloproteinases	\$85,800	2000 – 2002
Lisa L. Maduzia	Analysis of TGF B Signaling in C. elegans	\$33,000	1998 – 2000
Samuel Gunderson	Production of Secreted EGFR by Poly (4) Site Activation	\$86,900	1998 – 2000
Ruth Steward	Characterization of a New Ikb Interacting Protein in Mouse	\$87,890	1998 – 2000
Sam Gunderson	Production of Secreted EGFR by Poly (A) Site Activation	\$86,900	1998 – 2000
Corey Nislow	Analysis of SET1, A Yeast Homolog of the Oncogene	\$63,773	1994 – 1999
Howard Leventhal	Cognitive & Emotional Reaction to BRCA1& BRCA 2 Testing	\$40,000	1997 – 1999
Fumio Matsumura	Role of Fascin in Cell Transformation	\$44,000	1997 – 1998

Grants: 1983 – 2008

Susie Chen	Characterization of Transgenic Mice Predisposed to Melanoma	\$42,130	1997 – 1998
Steven Brill	Molecular Analysis of the Blooms/Werner's Syndrome Homolog	\$30,729	1997 – 1997
Susan Rittling, PhD	Role of Osteopontin in Normal and Neoplastic Mammary Gland	\$43,450	1996 – 1997
Kenneth Irvine	Control of Cell Proliferation by TEF - 1Scalloped	\$76,947	1996 – 1998
Richard Padgett	Upstream Signaling of TGF - B in <i>C. elegans</i>	\$43,977	1996 – 1997
Michael Toledano	Analysis of Yeast Oxidant Stress and Cellular Redox Control	\$40,763	1996 – 1997
Carl Schaffner	Hamster Prostate Carcinogenesis	\$44,000	1996 – 1997
Suzie Chen	Characterization of Transgenic Mice Predisposed to Melanoma	\$44,000	1996 – 1997
Susan Rittling, PhD	Role of Osteopontin in Normal & Neoplastic Mammary Glands	\$42,175	1995 – 1996
Elise L. Lev	Effects of Chemocare Program on Cancer Survivors & Families	\$30,000	1995 – 1996
Noshir A. Langrana	Development of Training Tools in Palpation of Breast Lesions	\$40,000	1995 – 1996
David Axelrod, PhD	Role of DNA Methylation in Tumor Cell Heterogeneity	\$44,000	1995 – 1996
Jeffrey Way	Molecular Mechanisms of Asymmetric Cell Division	\$44,000	1994 – 1995
Richard Ebright	DNA Binding by MYC and MAX	\$42,860	1994 – 1995
Julie Fagan	Iron, Free Radicals and Cancer	\$84,810	1994 – 1997
David Axelrod	Role of DNA Methylation in Tumor Cell Heterogeneity	\$44,000	1994 – 1995
Jun Yan Hong	Inhibition of Tumorigenesis by Organosulfur Compounds from Garlic	\$82,346	1993 – 1995
Carol Gardner	The role of Nonparenchymal Cells in Tumor Induced Liver Dysfunction	\$84,259	1993 – 1995
C.S. Yang	A Workshop on Cancer Research in New Jersey	\$24,145	1993 – 1995
William Sofer	Study of ELAV, A Drosophila Neuronal HU Antigen Homolog	\$40,150	1993 – 1994
Leonard Rabinow	Substrates of an Evolutionarily Conserved Protein Kinase	\$43,989	1993 – 1994
Lenore Neigeborn	Mutational and Genetic Analyses of the MDK1 Protein Kinase	\$42,501	1993 – 1994
Kathleen Hagen	A New Rat Model for Human Intravesical Bladder Cancer	\$22,708	1993 – 1994
William Sofer	Study of ELAV, a Drosophila Neuronal HU Antigen Homolog	\$42,818	1992 – 1993
Leonard Rabinow	A Complex Regulator of Drosophila Transcript Accumulation	\$43,182	1992 – 1993
Richard Padgett	In Vivo Structure/Function TGF – Beta	\$84,586	1991 – 1993
Dona Schneider	NJ Pediatric Cancer Databases	\$41,980	1990 – 1992
Edward Yurkow	Regulation of Insulin Receptor	\$85,237	1990 – 1992
Arthur Greenberg	Study of Silatranes: Inhibitors	\$58,993	1990 – 1992
Alan Appleby	Radiation Dose Distribution	\$83,875	1989 – 1991
Gregory Hamm	Network Services for CA researchers	\$32,690	1989 – 1990
Bernadette West	Proposal for Development of Cancer Research Infrastructure in NJ	\$23,023	1988 – 1989
M. Greenberg	Evaluation of Black & Indiv. Data Sets	\$67,900	1988 – 1989
Rashida Karmali	Role of Dietary Fatty Acids in Breast Cancer	\$86,460	1988 – 1990
David Axelrod	Genes Ras Transformation	\$43,670	1987 – 1989
J. Goldenthal	Oncogene Function	\$61,424	1987 – 1989
John D. Rosen	Quantification of Food Mutagens	\$71,808	1986 – 1988
Rashida Karmali	Omega - 3 Fatty Acids & Breast CA	\$75,385	1986 – 1988
Rashida Karmali	Nutrition and Breast Cancer	\$43,368	1985 – 1986
David Axelrod	New Genes Which Support Ras	\$45,255	1984 – 1986
Warren Maltzman	Cellular Imortalization	\$87,264	1984 – 1986
Kuang Yu Chen	Protein Phosphorylation	\$85,828	1984 – 1986

ST. MICHAEL'S MEDICAL CENTER, NEWARK

Diana Lake – Lewin Immune Status and Breast Cancer \$95,915 1988 – 1989

ST. PETER'S MEDICAL CENTER, NEW BRUNSWICK

Karel F. Raska, Jr Man6P Glycoproteins and Poor Survival in Breast Cancer \$50,000 1996 – 1997

Karel F. Raska, Jr Man6pg and Prognosis in Ovarian and Prostate Cancer \$42,900 1995 – 1996

UMDNJ – NEW JERSEY MEDICAL SCHOOL

Melissa B. Rogers Mycoplasma and BMP2 in lung cell transformation \$130,900 2008 – 2010

Renping Zhou Novel Regulation of Skin Carcinogenesis by Ephrin-A5 and EphA2 \$132,000 2008 – 2010

Lawrence E. Harrison In vivo thermal sensitization of intraperitoneal chemotherapy \$132,000 2008 – 2010

Utz Herbig Tumor Suppression by Telomere Dysfunction Induced Senescence \$130,900 2008 – 2010

Pranela Rameshwar Mesenchymal stem cell as cancer target in bone marrow \$66,000 2008 – 2009

Shridar Ganesan Immune Infiltrates in HER2+ breast cancer \$57,130 2008 – 2009

Janine H. Santos Mitochondrial telomerase and its impact in prostate cancer \$49,500 2008 – 2009

Yongkyu Park Function of Non-coding RNA, roX, in Gene Expression \$49,500 2007 – 2008

Nicole Pannucci c-Myc in Chronic Myelogenous Leukemia \$38,000 2006 – 2007

Richard Eckner Role of p300/CBP in Id Expression and Breast Cancer \$96,800 2005 – 2007

Oyenike Olabisi A Novel Function for Bcr in Chronic Myelogenous Leukemia \$38,000 2005 – 2007

Yongkyu Park Cis-spreading Mechanism of MSL Complex in Chromatin \$96,800 2005 – 2007

Sophia Spadavecchia Cellular Notch Signaling and Herpesvirus Pathogenesis \$38,000 2005 – 2007

Bernadette Cracchiolo Genital Intraepithelial Neoplasia and Hypusination \$49,500 2005 – 2006

Katsunori Sugimoto Mechanism for Recruiting Checkpoint-Mediator
Proteins to DNA Lesions \$97,350 2004 – 2006

Andreas Ivessa Mechanisms of Mitochondrial DNA Inheritance \$97,240 2004 – 2006

Kyla Driscoll Role of Dimerization of Rta in KSHV Lytic Reactivation \$38,000 2004 – 2006

Raymond Birge A Novel Strategy to Target Dendritic Cells \$49,500 2004 – 2006

Kar Bishnupirya A Novel Nuclear Role for the Crk Oncogene \$38,000 2004 – 2006

Massimo Pinto Radiation-induced Bystander Effects in a 3D Model \$69,000 2004 – 2005

Bogdan Gerashchenko Effects of Radiation on Unirradiated Bystander Cells \$58,050 2003 – 2005

Shobha Gunnery Role of PKR in Growth Control of Breast Cancer Cells \$50,000 2003 – 2005

Carlos Molina Ras-mediated Proteasomal Degredation of ICER in Melanoma \$98,865 2003 – 2005

Naomi Bergman Regulation of mRNA Turnover in Mammalian Cells \$33,000 2002 – 2004

Yan Ji Signaling of Differentiation by 1,23D3 in Leukemia Cells \$33,000 2002 – 2004

David Lukac Synergy of KSHV ORF57 with the Viral Lytic Switch Protein \$48,901 2002 – 2004

William Simmons Role of CD30 in the Growth Promotion of SJL Lymphomas \$33,000 2002 – 2004

Tsafi Peery Granulin: Cyclin T1 Interactions in Breast Cancer \$100,000 2002 – 2004

Hua Zhu A Novel Cytomegalovirus-Initiated Signal Pathway \$49,500 2002 – 2003

Edouard I. Azzam Signaling from Irradiated to Non-Irradiated Cells \$99,000 2001 – 2003

Lawrence Harrison PPARγ: A Mechanism of Phenylbutyrate-Induced Apoptosis \$95,300 2001 – 2003

David M. Lukac Viral Reactivation of KSVH in Primary Effusion Lymphoma \$96,702 2001 – 2003

Brian McCarthy The Role of IL-10 in B-1 Malignancies \$33,000 2001 – 2003

Sukhwinder Sing Phagocytosis, Cross-Priming, and Tumor Immunity \$33,000 2001 – 2003

Nicholas Megjugorac IFN-Producing Dendritic Cells in Cellular Immunity \$33,000 2000 – 2002

Trevor Reichman Role of NF90 in Regulation Transcription and Cell Cycle \$33,000 2000 – 2002

Reju Korah Abrogation of Inside Out Signaling Reverses
Breast Cancer Morphology \$98,840 2000 – 2002

Grants: 1983 – 2008

Joel Lefferts	Spectrin and the DNA Repair Defect in Fanconi Anemia	\$33,000	2000 – 2002
Ian P. Whitehead	Cloning of Novel, Breast Specific Oncogenes by Use of Retroviral cDNA Libraries	\$49,543	1999 – 2000
Lisa Parker	Regulation of an NFAT Site Binding Protein by RNA	\$58,050	1998 – 2000
Robert Wieder	Differentiation of Breast Cancer by Retinoids & Vitamin D	\$50,000	1998 – 1999
Carlos Molina	Transcriptional Repressor ICER1g and Cell Transformation	\$88,000	1996 – 1998
Jeffrey Wilusz	Mechanism of mRNA Stabilization by Poly (A)	\$44,000	1996 – 1997
Nicholas Ponzio	Use of Human Umbilical Cord Blood Cells	\$42,020	1995 – 1997
Patricia Bocarsly	Signaling Pathways in Accessory Cell Dependent NK Lydd	\$88,000	1995 – 1997
Laura T. Goldsmith	Growth of Ki - ras Gene Amplified Human Ovarian Carcinoma	\$44,000	1994 – 1995
G. Reza Najem	A Model for Increasing Breast & Cervical Cancer Screening	\$49,940	1993 – 1994
Surienda Kumar	Neoplastic Transformation of Human Cells Nickel Compounds	\$42,130	1993 – 1994
Laura Goldsmith	Growth of Ki - Ras Gene Amplified Ovarian Carcinoma Cells	\$37,213	1993 – 1994
George Studzinski	Cellular Adaptions in ARA - C Resistant Leukemia Cells	\$36,709	1992 – 1993
Gursurinder Kaur	Genetic Analysis of Cell Growth in Brain Tumor Cells	\$83,325	1992 – 1994
Zafri Humanyun	Basic Mechanisms of Estrogen Induced Cancer	\$39,490	1992 – 1993
Jeffrey Wilusz	Protein Factor in Tumor	\$31,900	1991 – 1992
Michael Small	Revertants of Rat Fibroblasts	\$39,050	1991 – 1992
Nicholas Ponzio	The Host Immune System	\$83,362	1990 – 1992
Jeffrey Wilusz	Characterization of AAUAAA	\$26,950	1990 – 1991
Dandamudi Rao	Radiological Effects of Alpha	\$86,460	1989 – 1991
David Kaback	Control of Recombination	\$44,000	1989 – 1991
Harvey Ozer	Roles of the Retinoblastoma Gene	\$44,000	1989 – 1991
Reza Najem	Pilot Study in Preventive Oncology	\$98,285	1989 – 1991
Amaresh Basu	Studies on ras p 21	\$87,670	1988 – 1990
Helene Z. Hill	Novel Approaches to Melanoma	\$86,020	1988 – 1990
John D. Bodgen	Effects of Zinc on Tumor Immunity	\$87,943	1988 – 1990
Karimullah Zirvi	Studies of Human Colon Tumor Cell	\$87,780	1988 – 1990
L. F. Pliner	Influences of Polyamines on Human	\$85,762	1988 – 1990
Mukund Modak	DNA Polymerase Complex from Leukemic	\$44,000	1988 – 1990
Roger Howell	Distribution & Radiotoxicity	\$83,325	1988 – 1990
Marvin Lavenhar	Cancer Risk Factors in Economically Disadvantaged	\$79,493	1988 – 1989
Reza Najem	Pilot - Preventive Oncology	\$88,220	1988 – 1989
Helene Z. Hill	Radiation Carcinogenesis	\$44,000	1987 – 1989
L.C. Schneider	Micronuclei in Oral Mucosa	\$77,088	1987 – 1989
Pedro Gascon	Predictive Markers in Leukemic Cells	\$76,273	1987 – 1989
Abraham Aviv	Mitogenic Stimuli & Cellular Na+	\$74,576	1986 – 1988
Mukund J. Modak	Structure - Function Relationships	\$76,681	1986 – 1988
Muriel Lambert	Repair of DNA Interstrand Cross Links	\$75,141	1986 – 1988
Susan C. Feldman	Neuropeptides	\$85,316	1986 – 1988
Edward J. Flynn	Benzo (a) pyrene	\$48,884	1985 – 1986
G. di Mayorca	Transforming Genes of Simian	\$81,400	1985 – 1986
Joesph J. McArdle	Role of Membrane Ion Transport	\$43,824	1985 – 1986
Linda Plapinger	Studies of Adenosis	\$68,999	1985 – 1986
M. Zafri Humayun	Carcinogen - Induced Mutation	\$76,780	1985 – 1986
Nicholas Ponzio	Influence of Lymphokines	\$80,300	1985 – 1986

George Studzinski	Mechanism of Vitamin D	\$85,672	1985 – 1987
Jeong Sook Yoo	Mechanisms of the Metabolic	\$83,272	1985 – 1987
Lynn S. Ripley	Frameshifts Mechanisms	\$77,000	1985 – 1987
Marjorie Brandriss	Mitochondrial Biogenesis	\$84,832	1985 – 1987
Raghubir S. Athwal	Carcinogen – Induced	\$81,400	1985 – 1986
Alan Pater	Role of BKV Genes	\$82,096	1984 – 1986
Chang S. Yang	Mechanisms of Alcohol Induced	\$88,000	1984 – 1986
David Kaback	The Role of Differentially	\$87,996	1984 – 1986
Helene Z. Hill	The Role of Oxygen	\$88,000	1984 – 1986
Lawrence Feldman	Genetic Targets	\$69,905	1984 – 1986
Marian L. Harter	Site - Directed Mutations	\$64,622	1984 – 1986
Michael A. Lea	Neoplasia and Metabolite	\$84,490	1984 – 1986
M. Zafri Humayun	Sequence Specificity	\$88,000	1984 – 1986
Richard Feinberg	Embryonic Angiogenesis	\$74,756	1984 – 1986

UMDNJ - ROBERT WOOD JOHNSON MEDICAL CENTER

Vassiliki Karantza-Wadsworth	Breast Cancer Growth Modality/Genotype and Treatment	\$99,000	2007 – 2009
Chih-Cheng Tsai	Roles of Atrophin Proteins in Prostate Cancer	\$49,500	2007 – 2008
Yi Lisa Lyu	Molecular Basis for Doxorubicin Cardiotoxicity	\$49,500	2007 – 2008
Huizhou Fan	Control of TACE-mediated TGF- α Release in Cancer	\$49,500	2006 – 2008
Emmanuel Gabriel	Effects of Treg Modulation on Vaccine Immunotherapy	\$40,000	2006 – 2008
Celine Gelinias	Role of CAPER in ER and NF- κ B Activity in Breast Cancer	\$99,000	2006 – 2008
Estela Jacinto	Phosphorylation of Target of Rapamycin Complexes in Growth Regulation	\$97,500	2006 – 2008
Yi Lyu	Role of Topoisomerase II Isozymes in Carcinogenesis	\$99,000	2006 – 2008
Sonia Picincich	Mechanisms of Mesenchymal Stem Cell Homing to Tumors	\$40,000	2006 – 2008
Akira Sato	A New Factor in Canonical Wnt Signaling	\$70,500	2006 – 2008
Victoria Swiss	Direct Discovery of Msx1 Target Genes in Breast Tissue	\$40,000	2006 – 2008
Nagarajan Selvamurugan	TGF- β Action on Human Breast Cancer Cells	\$97,900	2005 – 2007
Chi Shin-Darlak	Characterization of a Silenced Chromatin from Yeast	\$69,000	2005 – 2007
Bruce I. Sodowich	Modeling Topoisomerase I/Camptothecin DNA Damage In Vivo	\$33,000	2005 – 2007
Adrienne Black	Mechanisms of Ultraviolet Light Carcinogenesis	\$38,000	2005 – 2007
Patrizia Casaccia-Bonnel	Defective Epigenetic Changes in the Genesis of Gliomas	\$49,500	2005 – 2006
Seymour Garte	Breast Cancer and Estrogens in African Americans	\$27,500	2005 – 2006
Shengkan Jin	Study of Tumor Suppression Mechanisms of Autophagy	\$96,800	2004 – 2006
Yuh-Hwa Wang	Chromatin Structure of Cancer Specific Fragile Sites	\$88,000	2004 – 2006
Leland Gershell	Hmga2 in Mammary Tumorigenesis and Metastasis	\$69,000	2004 – 2006
Roderich Schwarz	Ras Inhibition and Antiangiogenic VEGF-Directed Therapy of Pancreatic Cancer	\$97,900	2003 – 2006
Sankarsharma Devipiriya	Role of Hmga2 in Colon Cancer	\$58,050	2003 – 2005
Huizhou Fan	Regulation of TGF- α Release in Cancer	\$99,000	2003 – 2005
Rimma Belotserkovskaya	Cellular and Molecular Mechanism of FACT	\$58,050	2003 – 2005
T.J. Thomas	Targeting NF- κ B by Peptide Nucleic Acids in Breast Cancer	\$50,000	2003 – 2005
Krishna Kesari	Role of HMGI-C Protein in Breast Cancer	\$100,000	2002 – 2004
Jerome Kucharczak	Antiapoptotic and Oncogenic Function	\$58,050	2002 – 2004

Grants: 1983 – 2008

Shah Nur-E-Kamal	Role of Non-Receptor Tyrosine Kinase, Ack in Transformation	\$99,000	2000 – 2002
Traci Czyzyk	Genetic Analysis of Peptide Amidation in Tumorigenesis	\$33,000	2000 – 2002
Ramsey Foty	Prostate Tumor Cohesively and Organ Targeting	\$49,500	2000 – 2001
Nancy J. Genatt	The Effect of Comorbidity on Breast Cancer Survival in New Jersey Women	\$24,000	1999 – 2001
Daniel S. Pilch	Mechanism of Action of a New Class of Topoisomerase I Protein	\$83,204	1999 – 2001
Surguei V. Kotenko	New Member of the Class II Cytokine Receptor Family	\$44,000	1999 – 2000
Kyoung-Eun Kim	Functional Analysis of the bci-3 Protooncogene	\$58,050	1998 – 2000
Cherylene A. Schaubert	Regulation of DNA Repair by the Ubiquitin System	\$58,050	1998 – 2000
Stacy Stein	Isolation of Genes Regulated by Nkx3.1	\$33,000	1998 – 2000
Jeffrey R. Cook	New Interferon Receptors in Normal and Transformed Cells	\$85,690	1998 – 2000
Thresia Thomas	Estrodiol Metabolites and Breast Cancer	\$50,000	1998 – 1999
Terri Goss Kinzy	In Vivo Effects of the PTI - 1 Prostatic Tumor Promoting Factor	\$42,900	1998 – 1999
John Lenard	Phosphocalmodulin in Cell Cycle and Cancer	\$84,622	1997 – 1999
Terri Kinzy	In Vivo Effects of the PT1 - 1 Prostatic Tumor Promoting Factor	\$41,800	1997 – 1998
Jonathan Dinman	Ribosomal Frameshifting and Cellular Gene Expression	\$33,550	1997 – 1998
Nancy Woyckik	Transcriptional Regulation of Cell Growth by RNA Polymerase	\$88,000	1996 – 1998
T.J. Thomas	Estrogen and Cell Cycle in Breast Cancer: A34kDa Protein	\$44,000	1996 – 1997
Jonathan Dinman	Cellular Gene Expression Control by Ribosomal Frameshifting	\$42,350	1996 – 1997
Kiran Madura	Studies on Ubiquitin - Conjugation and Transfer	\$87,340	1995 – 1997
Thresia Thomas	Triplex DNA as an Anti - Gene Strategy for	\$42,900	1995 – 1996
Tariq Rana	The Molecular Mechanism of Tumor Suppression by P53	\$42,350	1995 – 1996
Reuben Mezrich	In Vivo Temperature Measurement by MRI	\$44,000	1995 – 1996
Marc Gartenberg	Chromosome Architectute	\$88,000	1994 – 1997
Ralph Dornburg	A Model System to Study Gene Therapy of Breast Cancer	\$88,000	1994 – 1996
Michael Gallo	Enhancement of Cancer Prevention and Control Research Programs	\$20,907	1994 – 1996
Charles Boyd	Lysy1 Oxidase Gene Mutations in Colon Cancer	\$87,907	1994 – 1996
Tariq Rana	The Molecular Mechanism of Tumor Suppression by P53	\$43,450	1994 – 1995
Thresia Thomas	Triplex DNA as an Anti - gene Strategy for Breast Cancer	\$44,000	1994 – 1995
Beate Schwer	Functional Analysis of the Splicosomes AtPase PrP16	\$39,600	1993 – 1994
Ralph Dornburg	Retroviral Vectors Containing Chimeric Envelope Proteins	\$44,000	1993 – 1994
Susan Quinones	Regulation of Transformation Induced Stromelysin Expression	\$82,449	1992 – 1994
Joseph Dougherty	Cloning of the Receptor Gene for Type D Simian Oncoretrovirus	\$43,100	1992 – 1993
Ralph Dornburg	Retroviral Vectors Containing Chimeric Envelope Proteins	\$41,800	1992 – 1993
Lynne D. Vales	Functional Domains of Adenovirus	\$40,920	1991 – 1992
Celine Gelinas	Functional Analysis v - rel Oncoprotein	\$68,924	1990 – 1992
Julian O'Rear	Molecular Genetic Studies – Laminin	\$77,378	1990 – 1992
Sean O'Connell	Correlation of Genetic Rearrangements	\$85,446	1990 – 1992
George I. Karp	The Biology & Biochemistry of Blood	\$86,192	1989 – 1991
Jerome Langer	Characterization of Alpha Interferon	\$87,725	1989 – 1991
Kiron Moy Das	Diagnosis & Immunotherapies of Colon	\$78,100	1989 – 1991
Leigh Wise	Isolating Adipose Commitment cDNA	\$87,876	1989 – 1991
Scott Powers	Function of Ras in Growth Factors	\$82,500	1989 – 1991
Danny Reinberg	Adenovirus Transforming Genes	\$83,160	1988 – 1990
Fredika Robertson	Tumor Promotion & Epidermal Immune	\$86,460	1988 – 1990
Sueihua Pan	Immune Control of DNA Virus Induced	\$80,693	1988 – 1990

Jed Waldman	Direct Assessment of Human Radon Exp	\$92,774	1988 – 1989
Danny Reinberg	Gene Control Adenovirus	\$87,406	1987 – 1989
Ellen Ebert	Immunosuppressive Colon	\$83,374	1987 – 1989
Kiran Chada	Gene Expression	\$88,000	1987 – 1989
Mark T. Takahashi	Transglutaminase Catalysis	\$86,460	1987 – 1989
Michael Leibowitz	Mitochondrial Replication	\$44,000	1987 – 1989
Paul March	Function of era in E. coli	\$76,620	1987 – 1989
Lawrence Ettinger	New Prognostic Factors in Pediatric	\$87,450	1987 – 1989
Masayori Inouye	mic RNA Immune System	\$88,000	1987 – 1989
Jeffrey Laskin	Role of Activated Macrophages	\$81,262	1986 – 1988
Dennis Devereux	Serum Lipolytic Activity	\$38,500	1985 – 1986
M. Brostrom	Mechanism of Action of Tumor Prom	\$44,000	1985 – 1986
Alex Eichholz	Organospecificity of Cancer Tissue	\$76,585	1985 – 1986
John Holowczak	Vaccinia Virus Induced Immunity	\$85,928	1985 – 1987
M. Brostrom	Mechanism of Action of Tumor Prom	\$32,444	1985 – 1987
Michael Liebowitz	Genetics of Mitochondrial Replica	\$88,000	1985 – 1987
Ralph S. Greco	Collagen Biosynthesis in Breast Cancer	\$77,283	1985 – 1987
William McAllister	Studies of Recombination in Papilloma	\$83,233	1985 – 1987
Karl Tryggvason	Role of Type IV Collagenase	\$88,000	1984 – 1986
Linda Hsu	Effects of Tumor Promotion	\$64,216	1984 – 1986


VA NEW JERSEY HEALTH CARE SYSTEM

Victor T. Chang	Comorbidity and survival in patients with advanced cancer	\$113,684	2008 – 2010
RuiRong Yuan	Immunotargeting Therapy for Small Cell Lung Cancer by Anti-HuD-Toxin Complexes	\$97,900	2006 – 2008
Shirley Hwang	Longitudinal Cancer Care & Pain Survey	\$34,320	1995 – 1997



24.....Returning \$10 to New Jersey for Every Research \$1 Awarded

25 Year Grant Totals



CANCER INSTITUTE OF NEW JERSEY

Susan Lee	Summer	\$4,000	2008 – 2009
Pinxia Chen	Summer	\$4,000	2008 – 2009
YongJie Chen	Summer	\$4,000	2008 – 2009
Michael Patel	Summer	\$4,000	2008 – 2009
Timothy McCarthy	Summer	\$4,000	2006 – 2007
Roshan Desai	Summer	\$2,800	2003 – 2004
Kelly Burk	Summer	\$2,800	2002 – 2003
Derek R. Taller	Differential Gene Profiling of C-Terminal p53 Mutants	\$33,000	2001 – 2003
Arvin S. Yang	Cytokine Optimization of Anti-Tumor Vaccines	\$33,000	2001 – 2003
Wilbert D. Yeung	Summer	\$2,800	2001 – 2002
Anthony Burgos	Summer	\$2,800	2000 – 2001
Elena Reitman	Summer	\$2,800	2000 – 2001
Jeremy M. Rosenblum	Summer	\$2,800	2000 – 2001
Judith Bash, PhD	Molecular Determinants of Sensitivity To Antimitotic Drugs	\$38,000	1999 – 2001

Pre-, Post- and Summer Fellowships, 1988-2008

CORIELL INSTITUTE OF NEW JERSEY

Rachel A. Patterson	Summer	\$2,800	2000 – 2001
---------------------	--------	---------	-------------

DREW UNIVERSITY

Karen McMurdie	Summer	\$4,000	2008 - 2009
Karen LeSuer	Summer	\$4,000	2007 – 2008

GARDEN STATE CANCER CENTER

Gopi M. Patel	Summer	\$3,200	2005 – 2006
Francesco DePierro	Summer	\$2,800	2004 – 2005
Janet Wangari	Summer	\$2,800	2004 – 2005
Roberto Zoino	Summer	\$2,800	2003 – 2004
Vanessa Nina	Summer	\$2,800	2002 – 2003
William D. Bradley	Summer	\$2,800	2001 – 2002
Noel A. DeVilla	Summer	\$2,800	2001 – 2002
Cynthia O. Okoduwa	Summer	\$2,800	2001 – 2002
Christein L. Flefleh	Summer	\$2,800	2000 – 2001
Marisol D. Rodriquez	Summer	\$2,800	2000 – 2001
Russell J. Craig	Summer	\$2,800	2000 – 2001
Michael S. Stein	Summer	\$2,800	2000 – 2001
Christopher J. Waskewich	Summer	\$2,800	2000 – 2001
Lori A. Fejko	Summer	\$2,800	1999 – 2000
Kevin Frischmann	Summer	\$2,800	1999 – 2000
Shefali Gandhi	Summer	\$2,800	1994 – 1994

KEAN UNIVERSITY

Sanjay Bhambri	Summer	\$2,800	1999 – 2000
----------------	--------	---------	-------------

PRINCETON UNIVERSITY

Christine M. O'Connor	Deciphering the Functions of the HCMVen Coded GPCRS	\$72,000	2008 – 2010
Christopoher E. Slagle	The Role of FoxH1 During Metastasis	\$45,000	2008 - 2010
Benjamin J. Tiede	The Role of Mammary Stem Cells in Carcinogenesis	\$45,000	2008 – 2010
Erin P. O'Keefe	Cellular Proteins in HCMV Induced Cell Cycle Alteration	\$45,000	2008 – 2010
Jean S. McGee	Riflp in Preferential Elongation of Short Telomers	\$45,000	2008 – 2010
Erin M. Haley	A Role for Autophagy in Prostate Cancer Stem Cells	\$45,000	2008 – 2010
Nilay Sethi	Involvement of Notch Pathway in Cancer Metastasis	\$45,000	2008 – 2010
Euphemia Mu	Summer	\$4,000	2008 – 2009
Lee Fisher	Summer	\$4,000	2008 – 2009
Walter Chen	Summer	\$4,000	2008 – 2009
Jeremy Amon	Summer	\$4,000	2008 – 2009
Caitlin Fay	Summer	\$4,000	2008 – 2009

Kupa Mutunga	Summer	\$4,000	2008 - 2009
Kieran Dilks, PhD	Four-Dimensional Characterization of <i>FOXO/DAF-16</i>	\$70,500	2007 – 2009
Alison Hottes, PhD	Tracking Mutational Effects Through Cellular Networks	\$70,500	2007 – 2009
Florian Ulrich, PhD	In Vivo Analysis of <i>EMT</i> During <i>Drosophila</i> Gastrulation	\$70,500	2007 – 2009
Ryan Norman	Investigating <i>Tulp 3</i> in Sonic Hedgehog Signaling	\$40,000	2007 – 2009
Johna Van Stelten	Effects of Treg Modulation on Vaccine Immunotherapy	\$40,000	2007 – 2009
Stuart Carter	Summer	\$4,000	2007 – 2008
Walter Chen	Summer	\$4,000	2007 – 2008
Tom Feng	Summer	\$4,000	2007 – 2008
Keren Glinert	Summer	\$4,000	2007 – 2008
Rajani Sharma	Summer	\$4,000	2007 – 2008
Aubrey Wagenseller	Summer	\$4,000	2007 – 2008
Guohong Hu, PhD	Metastasis Regulatory Programs of Breast Cancer	\$70,500	2006 – 2008
Wendy Shaw, PhD	Identification of Genes Required for Reproductive Aging	\$70,500	2006 – 2008
Humayra Ali	Optimization of an Adenoviral Vector for Cancer Therapy	\$40,000	2006 – 2008
Jane Philips	The Role of <i>Puf1p</i> in Telomerase Inhibition	\$40,000	2006 – 2008
Robert Chang	Summer	\$4,000	2006 – 2007
Eugene Fan	Summer	\$4,000	2006 – 2007
Alicia Hayes	Summer	\$4,000	2006 – 2007
Elizabeth Pollina	Summer	\$4,000	2006 – 2007
Danielle Ponzio	Summer	\$4,000	2006 – 2007
Christian Theriault	Summer	\$4,000	2006 – 2007
Eva Vertes	Summer	\$4,000	2006 – 2007
Amy Wasterlain	Summer	\$4,000	2006 – 2007
Carol Yan	Summer	\$4,000	2006 – 2007
Neal Chatterjee	Summer	\$3,200	2005 – 2006
Megan C. Feldt	Summer	\$3,200	2005 – 2006
Julia Manasson	Summer	\$3,200	2005 – 2006
Elenoe C. Smith	Summer	\$3,200	2005 – 2006
Eain A. Murphy	Mutational Analysis of Recently Identified HCMV ORF's	\$69,000	2004 – 2006
Kathleen Daumer	The Role of <i>Est3p</i> at the Telomere	\$38,000	2004 – 2006
Daryl Gohl	Mechanisms of Bithroax Complex Boundary Function	\$38,000	2004 – 2006
Martha Klovstad	Meiotic DSB and Checkpoint Activation	\$38,000	2004 – 2006
Eve Henry	Summer	\$2,800	2004 – 2005
Tolu Onigbanjo	Summer	\$2,800	2004 – 2005
Jean –Baptiste Boule, PhD	Functional Study of the Yeast Telomerase Heloenzyme	\$58,050	2003 – 2005

Pre-, Post- and Summer Fellowships, 1988-2008

Anders E. Lilja, PhD	Interaction of Cytomegalovirus with Tumor Cells	\$58,050	2003 – 2005
Brendan B. Richards	Indentification of Partners of <i>Fra-1</i>	\$33,000	2003 – 2005
Katherine N. Clouse	Restricted Gene Expression of <i>EGFR</i> Ligands	\$33,000	2003 – 2005
Rosemary Ku	Summer	\$2,800	2003 – 2004
Ruth Tennen	Summer	\$2,800	2003 – 2004
Kui Huang, PhD	Regulation of Cell Adhesion in Human Cancer	\$58,050	2002 – 2004
Jeonghyeon Park, PhD	Chromatin Modifying Complexes In <i>Myc</i> Oncogenesis	\$58,050	2002 – 2004
Amy E. Cocina	Structural Analysis of Two <i>C. elegans</i> Apoptotic Proteins	\$33,000	2002 – 2004
Ali Nouri	APC Tumor Suppressor's Role in Cell Migration	\$33,000	2002 – 2004
Scott J. Steele	Analyses of a Putative Imprinting Control Region	\$33,000	2002 – 2004
Nicholas S. Tolwinski	<i>Wnt</i> Signaling and the Control of Cell Morphology	\$33,000	2002 – 2004
Datsen Wei	Murine NKT Cell Development	\$33,000	2002 – 2004
Ishani Ganguli	Summer	\$2,800	2002 – 2003
Nnenka Offor	Summer	\$2,800	2002 – 2003
Dai Wang, PhD	Low-Molecular-Weight Proteins of Human Cytomegalovirus	\$58,050	2001 – 2003
Mellisande R. Wolf, PhD	Orb in Translation and <i>mRNA</i> Localization In Oncogenesis	\$58,050	2001 – 2003
Jessica B. Bressler	Telomeres and the <i>Rrm3p</i> Helicase	\$33,000	2001 – 2003
Sanjay J. Chandriani	Interactions between <i>Myc</i> and Chromatin	\$33,000	2001 – 2003
Dina P. Matheos	The Role of <i>Fus3p</i> in Cell Fusion	\$33,000	2001 – 2003
Susan E. Schweinsberg	Characterization of the <i>Fab7</i> Boundary Element	\$33,000	2001 – 2003
Ekaterina Semenova	Analysis of The Embryonic Lethal Detection Mutant <i>s-LAcrg</i>	\$33,000	2001 – 2003
Stacy C. Hwang	Summer	\$2,800	2001 – 2002
Yun-Sheen S. Liu	Summer	\$2,800	2001 – 2002
Farrah Mikhail	Summer	\$2,800	2001 – 2002
Afshan A. Nanji	Summer	\$2,800	2001 – 2002
Danielle M. Pierre	Summer	\$2,800	2001 – 2002
Ying Wang, PhD	Intergration of Nutrient-Activating Signaling Pathways	\$38,000	2000 – 2002
Julia A. Beaver	Summer	\$2,800	2000 – 2001
Tse-Sun Ku	Summer	\$2,800	2000 – 2001
Myeogwoo Lee, PhD	Characterization of Integrin Signaling In Vivo	\$38,000	1999 – 2001
Waheeda A. Khalfan	Genetic Analysis of the <i>SPB</i> Component Karlp in Yeast	\$20,000	1999 – 2001
Cassie A. Gyuricza	Summer	\$2,800	1999 – 2000

Matthew M. Ladra	Summer	\$2,800	1999 – 2000
Khoon-Yen E. Tay	Summer	\$2,800	1999 – 2000
Scott B. Vafai	Summer	\$2,800	1999 – 2000
Irena Ivanoska	Genetic Characterization of <i>MTOC</i> Duplication in Yeast	\$20,000	1998 - 2000
Anthony Apicelli	Summer	\$2,800	1998 – 1998
Sophie Dumont	Summer	\$2,800	1998 – 1998
Carrie Heusner	Summer	\$2,800	1998 – 1998
Heather Cheng	Summer	\$2,800	1997 – 1998
Katherine Heiden	Summer	\$2,800	1997 – 1998
Ann Marie Stroustrup	Summer	\$2,800	1997 – 1998
Gita Varprasthan	Summer	\$2,800	1997 – 1998
Julie Waterbury	Regulation of Cell Proliferation by the RNA Binding Protein Sex-lethal	\$25,000	1996 – 1998
Joseph T. Nickels	Ceramide-Mediated Signalling in <i>Saccharomyces Cerevisiae</i>	\$43,000	1996 – 1998
David Chang	The Regulation of the c-Myc Oncoprotein In Cellular Transformation	\$25,000	1996 – 1998
Sara Kantrow	Summer	\$2,800	1996 – 1996
Jan Sechler	Assembly of Fibronectin into a Fibrillar Matrix	\$20,000	1995 – 1997
Kristen Walker	Regulation of P 53 tumor suppressor Gene functions	\$38,000	1995 – 1996
Brian Elenbaas	The Role of the Mdm-2 Oncoprotein In Cancer	\$20,000	1995 – 1996
Hua Zhu	Postdoctoral	\$38,000	1994 – 1996
Leslie Pratt	Predocctoral	\$20,000	1994 – 1996
Kenneth D. Irvine	Postdoctoral	\$38,000	1994 – 1995
Yuqiao Shen	Identification & Characterization of Proteins that Regulate YY1 Activity	\$38,000	1993 – 1995
Shira F. Neuman	Signal Transduction in Oogenesis	\$38,000	1993 – 1994
Joseph H. Bayle	Identification of Cellular p53 Binding Proteins	\$30,000	1992 – 1995
R Hyde-DeRuyscher	The Role of junB in Adenovirus E1A Transactivation	\$38,000	1991 – 1993
Eyal Schejter	<i>Drosophila</i> Blastoderm in Cellularization Mutations	\$38,000	1991 – 1993
Anne M. Whalen	Biochemical Regulation of the Dorsal Gene Products	\$38,000	1991 – 1993
Brian Lewis	Isolation & characterization of MyoD- Related Genes in Hematopoietic Cells	\$30,000	1990 – 1993
Hilary Wilkinson	Predocctoral	\$30,000	1990 - 1993
Gautam Koo	Genetic Analysis of the <i>C. elegans</i> Lin 12 Gene	\$72,000	1990 - 1993
Robin Quartin	Characterization of p53 cDNAs Derived From Human Tumors	\$23,000	1990 – 1993
Karen Aguirre	To Master Recombinant DNA Technology And Biochemical Techniques	\$20,000	1989 – 1992

Pre-, Post- and Summer Fellowships, 1988-2008

Craig Jordan	Develop a Diverse & Comprehensive Knowledge of Cellular & Molecular Mechanisms of Blood Related Cancers	\$20,000	1989 – 1991
Georgoff Ingo	To Understand Leukocyte Entry into the Central Nervous System	\$38,000	1989 – 1991
Fern Bober	Postdoctoral	\$38,000	1988 – 1991
Shubha Govind	Postdoctoral	\$38,000	1988 – 1991
Mary Moore	Postdoctoral	\$38,000	1988 – 1991
Philip Hinds	Predocctoral	\$20,000	1988 – 1989

RIDER UNIVERSITY

Daniel Silberman	Summer	\$4,000	2006 – 2007
Grace Colletti	Summer	\$2,800	2004 – 2005
Patrick O'Keefe	Summer	\$2,800	2003 – 2004
Debra D. Cinco	Summer	\$2,800	1999 – 2000
KoKo F. Howell	Summer	\$2,800	1999 – 2000
Jason P. Smith	Summer	\$2,800	1998 – 1998
Robert Major	Summer	\$2,800	1997 – 1997
Evelyn Swain	Summer	\$2,800	1996 – 1996
Penelope J. Wermuth	Summer	\$2,800	1995 – 1995
Rannette Camacho	Summer	\$2,800	1995 – 1995
Daniel Weigh	Summer	\$2,800	1994 – 1994
Helen Cleveland	Summer	\$2,800	1994 – 1994
Anna M. Tuccillo	Summer	\$2,800	1994 – 1994

RUTGERS, THE STATE UNIVERSITY

James Monaco	Detecting Pre-malignant Prostate Lesions using MRI	\$72,000	2008 – 2010
Kevin P. Nikiteczuk	Immune Targeting Engineered Vaccine Delivery System	\$45,000	2008 – 2010
Lindsay D'Annunzio	Summer	\$4,000	2008 – 2009
Matthew Zegarek	Summer	\$4,000	2008 – 2009
Robert Toth	Summer	\$4,000	2008 – 2009
Zhama Hakhverdyan	Summer	\$4,000	2008 – 2009
Vanessa Palka	Summer	\$4,000	2008 – 2009
Saquib Malik	Summer	\$4,000	2008 – 2009
Amanda Mei	Summer	\$4,000	2008 – 2009
Monai Mehta	Summer	\$4,000	2008 – 2009
Rohan Mathur	Summer	\$4,000	2008 – 2009
Joseph Maffei	Summer	\$4,000	2008 – 2009
Miho Maeda	Summer	\$4,000	2008 – 2009
Jay Naik	Summer	\$4,000	2008 – 2009
Eric LaBouff	Summer	\$4,000	2008 - 2009
Brian Onken	Genetic Dissection of a Documented Anit-Cancer State	\$70,500	2007 – 2009
Jonathan Chappelow	Detecting Prostate Cancer on 3T MRI: Image Registration	\$40,000	2007 – 2009

Kerri-Ann Norton	Computational Modeling of DCIS	\$40,000	2007 – 2009
Anibal Valentin	The Role of c-Rel in EBV- Medicated B Cell Survival	\$40,000	2007 – 2009
Shawna Bennet	Summer	\$4,000	2007 – 2008
Kristen Bridges	Summer	\$4,000	2007 – 2008
Valentina Marcelli	Summer	\$4,000	2007 – 2008
Matthew Zegarek	Summer	\$4,000	2007 – 2008
Hwa Jin Lee	Therapeutic Strategies for Melanoma	\$70,500	2006 – 2008
Vincent Shen	Regulation of mRNA Decay Pathways And Cancer	\$40,000	2006 – 2007
Lili Chan	Summer	\$4,000	2006 – 2007
Daniel Hess	Summer	\$4,000	2006 – 2007
Paul Kirkpatrick	Summer	\$4,000	2006 – 2007
Olga Kravchuck	Summer	\$4,000	2006 – 2007
Boran Li	Summer	\$4,000	2006 – 2007
Shruti Parkh	Summer	\$4,000	2006 – 2007
Joseph F. Porter III	Regulation of RNA Decay in Activated/Transformed B Cells	\$69,000	2005 – 2007
Mousumi Bose	EGCG and Omega-3 PUFA in Colon Cancer Prevention	\$38,000	2005 – 2007
Kristen R. Bodtmann	Summer	\$3,200	2005 – 2006
Aaron Carlson	Summer	\$3,200	2005 – 2006
Jung C. Chang	Summer	\$3,200	2005 – 2006
Shyam Patel	Summer	\$3,200	2005 – 2006
Aaron Carlson	Summer	\$2,800	2004 – 2005
Sara Khalil	Summer	\$2,800	2004 – 2005
Jason Raines	Summer	\$2,800	2004 – 2005
Sun Xiaonan	Summer	\$2,800	2004 – 2005
Gabriella Alexe	Collective Biomarkers in Breast And Prostate Cancer	\$58,050	2003 – 2005
Kristina T. Lu	Analysis of a CD40 Related B Cell Proliferation Defect	\$33,000	2003 – 2004
Tara L. Broccoli	Special Fellowship	\$2,800	2003 – 2004
Kerry A. Hennessy	Special Fellowship	\$2,800	2003 – 2004
Natasha Henry	Special Fellowship	\$2,800	2003 – 2004
Theresa M. Viggiano	Special Fellowship	\$8,500	2003 – 2004
Dan Wang	Special Fellowship	\$2,800	2003 – 2004
Jinling Wei	Special Fellowship	\$2,800	2003 – 2004
Weiman Zhang	Special Fellowship	\$2,800	2003 – 2004
Leah Alabonza	Summer	\$2,800	2003 – 2004
Jay Oza	Summer	\$2,800	2003 – 2004
Mahesh Yaragatti	Summer	\$2,800	2003 – 2004
David Kingery	Summer	\$2,800	2002 – 2003
Cheng Larry	Summer	\$2,800	2002 – 2003
Jason Luciano	Summer	\$2,800	2002 – 2003
Ronald Myers	Summer	\$2,800	2002 – 2003
Hammad Rizvi	Summer	\$2,800	2002 – 2003

Pre-, Post- and Summer Fellowships, 1988-2008

Jeong Deok Shaefer	Summer	\$2,800	2002 – 2003
Jack Tasi	Summer	\$2,800	2002 – 2003
Robert J. Major	Analysis of Notch Signaling in Organized Tissue Growth	\$33,000	2001 – 2002
Shin-Wu Liu	Summer	\$2,800	2001 – 2002
Beatrice Rayet	Functional Characterization of <i>v-Rel</i> in Oncogene	\$38,000	2000 – 2001
Cole Zimmerman	Cell Cycle Regulation by TGF Signaling in <i>C. elegans</i>	\$38,000	2000 – 2001
Rajula Bhatia-Guar	The Role of <i>Nkx3.1</i> in Prostate Cancer	\$38,000	1999 – 2000
Darren N. Seril	Molecular Mechanism of Ulcerative Colitis-Carcinogenesis	\$20,000	1999 – 2000
Stephanie R. Dondzill	Summer	\$2,800	1999 – 2000
Janice Pieretti	Summer	\$2,800	1999 – 2000
Dragana Rogulia	Summer	\$2,800	1999 – 2000
Kevin Velasco	Summer	\$2,800	1999 – 2000
Lisa Madurzia	Analysis of TGF <i>B</i> signaling in <i>C. elegans</i>	\$20,000	1998 – 2000
Adam Lazorchak	Summer	\$2,800	1998 – 1998
Andrea E. Bowen	Summer	\$2,800	1998 – 1998
Marissa Frankhanel	Summer	\$2,800	1997 – 1997
David Axelrod	Oncoprotein Analysis of Primary Cell Cultures from Human Breast Tumors	\$7,500	1996 – 1997
Ian R. Orevillo	Summer	\$2,800	1996 – 1996
Stephania Borbe	Summer	\$2,800	1996 – 1996
Cathy Savage	TGF-B Signal Transduction in the Nematode <i>C. elegans</i>	\$38,000	1995 – 1996
John A. Curtis, Jr.	Summer	\$2,800	1995 – 1995
Josh D. Blum	Summer	\$2,800	1995 – 1995
Bhargav K. Shukla	Summer	\$2,800	1994 – 1994
Rekesh D. Mistry	Summer	\$2,800	1994 – 1994
Marc A. Milano	Summer	\$2,800	1994 – 1994
Janice Mehnert	Summer	\$2,800	1994 – 1994
Michele Martinovic	Summer	\$2,800	1994 – 1994
Daniel S. Heffron	Summer	\$2,800	1994 – 1994
Lawrence A. Guarino	Summer	\$2,800	1994 – 1994
Suzanne E. Afonso	Predocctoral	\$20,000	1994 – 1997
Cynthia Bossie	Transforming Growth Factor-B Accessory Proteins	\$47,000	1993 – 1995
Lisa F. Feder	Nonparenchymal Cell Cytokines and Liver Cancers	\$38,000	1991 – 1994
Lesley Heyler	Mechanism of Benzene-Induced Hematotoxicity	\$38,000	1990 – 1993
Nancy Butnick	<i>Ras</i> Oncogene Cell Transformation: Reversion Mechanisms	\$38,000	1990 – 1993
Rita Alisauskas	T-Cell Vaccination for Treatment of Murine Lymphomas	\$38,000	1990 – 1993

Patricia Eagle	Structure/Function Studies of Adenovirus DBP	\$20,000	1990 – 1993
Theresa Smith	Summer	\$2,800	1989 – 1991
Jennifer Hu	Summer	\$2,800	1989 – 1990
Vaughn Cleghon	Study the Nature of Gene Regulation In Eucaryotes in his Investigation of Ad DBP	\$20,000	1989 – 1990
Ewa Wajnberg	Postdoctoral	\$38,000	1988 – 1991
Nancy Butnick	Postdoctoral	\$38,000	1988 – 1991
Stephen Rose	Predocctoral	\$20,000	1988 – 1991
Marla Babcock	Predocctoral	\$20,000	1988 – 1991

SETON HALL UNIVERSITY

David L. Fischer	Summer	\$3,200	2005 – 2006
Mario E. Urena	Website Development for Psychosocial/ Nursing Professionals	\$2,800	2003 – 2004
Priscilla Dzurich	Summer	\$2,800	2002 – 2003
Wendy Budin	Structured Psychoeducational Interventions For Women with Breast Cancer	\$7,500	1996 – 1997

STEVENS INSTITUTE OF NEW JERSEY

Tiffany Jow	Summer	\$4,000	2007 – 2008
-------------	--------	---------	-------------

UMDNJ - NEW JERSEY MEDICAL SCHOOL

Erica Salerno	The role of miRNAs and Cancer Stem Cell in CLL	\$45,000	2008 - 2010
Alexandra Terskiy	Multiple Myeloma Cell Growth Inhibition by an Opioid	\$45,000	2008 – 2010
Ethan Fitzpatrick	Regulation of GTPase Signaling by Sec 14p domains	\$45,000	2008 – 2010
Daniel Spencer, PhD	Targeting <i>IRF-5</i> Signaling for Cancer Chemotherapy	\$70,500	2007 – 2009
Pedro Rodriquez	Activation of <i>RhoB</i> in the Endosome By <i>Ccpgl</i>	\$40,000	2007 – 2009
Ahmet Tanceroglu	Development of a FRET-Based Digansotic Assay for CML	\$40,000	2007 – 2009
Aileen Gavin	Summer	\$4,000	2007 – 2008
Nichole Pannucci	c-Myc in Chronic Myelogenous Leukemia	\$38,000	2006 – 2008
Mili Mandal	Summer	\$4,000	2006 – 2007
Joanna Sesti	Summer	\$4,000	2006 – 2007
Oyenike O. Olabisi	A Novel Function for <i>Bcr</i> in Chronic Myelogenous Leukemia	\$38,000	2005 – 2007
Sophia Spadavecchia	Cellular Notch Signaling and Herpesvirus Pathogenesis	\$38,000	2005 – 2007
Farah Khadim	Summer	\$3,200	2005 – 2006
Massimo Pinto, PhD	Radiation-induced Bystander Effects In a 3D Model	\$69,000	2004 – 2006

Pre-, Post- and Summer Fellowships, 1988-2008

Kar Bishnupirya	A Novel Nuclear Role for the <i>Crk</i> Oncogene	\$38,000	2004 – 2006
Kyla Driscoll	Role of Dimerization of <i>Rta</i> in <i>KsHV</i> Lytic Reactivation	\$38,000	2004 – 2006
Bryan Benn	Summer	\$3,200	2004 – 2005
Luis C. Muniz	Regulation of ICER in Melanoma Development	\$33,000	2003 – 2005
Matensz Oprychal	Regulation of Stability of Proto-Oncogene mRNAs	\$33,000	2003 – 2005
Michael Lindy	Summer	\$2,800	2003 – 2004
Naomi Bergman	Regulation of mRNA Turnover in In Mammalian Cells	\$33,000	2002 – 2004
Yan C. Ji, PhD	Signaling of Differentiation by 1,25D3 In Leukemia Cells	\$33,000	2002 – 2004
William Simmons	Role of CD30 in the Growth Promotion Of SJL Lymphomas	\$33,000	2002 – 2004
Raakhee Mahajan	Summer	\$2,800	2002 – 2003
Brian A. McCarthy	The Role of IL-10 in B-1 Malignancies	\$33,000	2001 – 2003
Sukhwinder Sing	Phagocytosis, Cross-Priming, and Tumor Immunity	\$33,000	2001 – 2003
Nicholas Megjugorac	IFN-Producing Dendritic Cells in Cellular Immunity	\$20,000	2000 – 2002
Trevor Reichman	Role of NF90 in Regulation Transcription And Cell Cycle	\$20,000	2000 – 2002
Ilan Seth Weisberg	Summer	\$2,800	2000 – 2001
Shauna Hodge	Summer	\$2,800	1998 – 1998
Lisa Parker	Postdoctoral	\$38,000	1998 – 2000
Qin Wang	Modulation of Apoptosis by Basic FGF in Breast Cancer	\$43,000	1997 – 1999
Xuening Wang	Mechanisms of Bitamin D3-Induced Loss of Tumorigenicity	\$25,000	1997 – 1999
Laura W. McMahon	A Defective DNA Repair Protein in Fanconi Anemia	\$25,000	1996 – 1998
June Lee	Summer	\$2,800	1996 – 1996
Shane T. Simmons	Summer	\$2,800	1995 – 1995
Patel A. Sameer	Summer	\$2,800	1995 – 1995
SM Ramchandani	Summer	\$2,800	1995 – 1995
Andrew Klein	Summer	\$2,800	1995 – 1995
Joseph M. Grossman	Summer	\$2,800	1995 – 1995
Karen J. Finnigan	Summer	\$2,800	1994 – 1994
Yi Hsieh Chang	Summer	\$2,800	1994 – 1994
Holly S. Murphy	Predocctoral	\$20,000	1994 – 1997
H. Coleen Silva	Postdoctoral	\$38,000	1994 – 1996
Sridevi N. Dhanaraj	Postdoctoral	\$38,000	1994 – 1995
Bihai Peng	Postdoctoral	\$38,000	1994 – 1995
Daniel W. Brois	Repair of DNA Interstrand Cross-Links Human Cells	\$30,000	1993 – 1996

Ravi S. Harapanhalli	Chemical Radioprotectors Against Tissue-incorporated Radionuclides	\$38,000	1991 – 1994
Paramjeet Bagga	DNA Repair in Human Cells: Cloning of The Repair Genes	\$38,000	1991 – 1994
Sheela Amrute	TdT Containing Recombinase	\$38,000	1991 – 1994
Lisa Pettera	Role of Cytokines in Accessory Cell Dependent NK Lysis	\$20,000	1990 – 1991
Sudhir Sahasrabudhe	Mechanisms of Mutagenesis by Carcinogens	\$38,000	1989 – 1992
Venkateswara Narra	To Find Means of Protection from Radiation Exposure	\$38,000	1989 – 1992
Dondapati Chowdary	Working to Understand the Mechanism Involved in Cell Proliferation & Regulation	\$38,000	1989 – 1992
Kiranjit Ahluwalia	Working on HIV Reverse Transcriptase	\$38,000	1989 – 1992
R. Tirumalai	Postdoctoral	\$38,000	1988 – 1991
Maninder Sidhu	Postdoctoral	\$38,000	1988 – 1991
Gursurinder Kaur	Postdoctoral	\$38,000	1988 – 1991
Donna Howell	Postdoctoral	\$38,000	1988 – 1991
Ann Colucci	Predocctoral	\$20,000	1988 – 1991

UMDNJ - ROBERT WOOD JOHNSON MEDICAL SCHOOL

Kevin F. Anton	Role of Macrophages in Tumor Growth	\$45,000	2008 – 2010
Jay H. Oza	The Effect of Poly (ADP-Ribose) Polymerase (PARP)	\$45,000	2008 - 2010
Peter Mazari	Cloning a Viral Receptor on Human 143B Osteosarcomas	\$40,000	2007 – 2009
Alison Tuske	Study of Adult T-cell Leukemia Using Transgenic Mice	\$40,000	2007 – 2009
Manisha Bhattacharya	Summer	\$4,000	2007 – 2008
Akira Sato, PhD	A New Factor in Canonical <i>Wnt</i> Signaling	\$70,500	2006 – 2008
Emmanuel Gabriel	Effects of Treg Madulation on Vaccine Immunotherapy	\$40,000	2006 – 2008
Sonia Picinich	Mechanisms of Mesenchymas Stem Cell Homing to Tumors	\$40,000	2006 – 2008
Victoria Swiss	Direct Discovery of <i>Mx1</i> Target Genes In Breast Tissue	\$40,000	2006 – 2008
Nichole Pannucci	c-Myc in Chronic Myelogenous Leukemia	\$38,000	2006 – 2008
Melony Williams	Summer	\$4,000	2006 – 2007
Donglin Liu, PhD	Alternate Polyadenylation of <i>BMP2 mRNA</i> In Cancer Cells	\$69,000	2005 – 2007
Chi Y. Shin-Darlak, PhD	Characterization of a Slienced Chromatin From Yeast	\$69,000	2005 – 2007
Adrienne T. Black	Mechanisms of Ultraviolet Light Carcinogenesis	\$38,000	2005 – 2007
Zhe Chen	Summer	\$3,200	2005 – 2006
Ruchira S. Ranaweera	Summer	\$3,200	2005 – 2006
Robin Mathew, PhD	Mitotic Checkpoint Function and Cancer Chemosensitivity	\$35,000	2004 – 2005

Pre-, Post- and Summer Fellowships, 1988-2008

Carl Kunda	Summer	\$2,800	2004 – 2005
Kathleen Redpath-Perez	Summer	\$2,800	2004 – 2005
Rimma Belotserkovskaya	Cellular & Molecular Mechanism of FACT	\$58,050	2003 – 2005
Sankarasharma Devipiriya	Role of <i>Hmga2</i> in Colon Cancer	\$58,050	2003 – 2005
Hao Liu, PhD	An Expression-Based Predictor for Colorectal Cancer	\$58,050	2003 – 2005
Khen-Jim Lim	Summer	\$2,800	2003 – 2004
Hari Narayan	Summer	\$2,800	2003 – 2004
Jerome F. Kucharczak, PhD	Antiapoptotic & Oncogenic Function Of <i>Ffl-1/A1</i>	\$58,050	2002 – 2004
Stephanie Nnadi	Summer	\$2,800	2002 – 2003
Michele M. Hickey	Summer	\$2,800	2001 – 2002
Traci Czyzyk	Genetic Analysis of Peptide Amidation In Tumorigenesis	\$20,000	2000 – 2001
Julie Yang	Summer	\$2,800	2000 – 2001
Bruce I. Sadowich	Modeling Topoisomerase I/Camptothecin DNA Damage In Vivo	\$20,000	1999 – 2000
Adam Shumate	Summer	\$2,800	1999 – 2000
Kyoung-Eun Kim	Functional Analysis of the <i>bci-3</i> Protooncogene	\$38,000	1998 – 2000
Sameh Girgis	Summer	\$2,800	1998 – 2000
Weng-Lang Yang	The Role of <i>R1</i> .Subunit of <i>PKA</i> in Cell Growth Regulation	\$38,000	1998 – 1999
Stacey Stein	Isolation of Genes Regulated by <i>Nkx3.1</i>	\$20,000	1998 – 1999
James Lee	Summer	\$2,800	1998 – 1998
Michael Shin	Summer	\$2,800	1998 – 1998
Christopher Krause	Interferon Gamma Signal Transduction	\$20,000	1997 – 1999
Cailin Chen	Anti-apoptotic Effect of <i>Rel</i> Toward Chemotherapeutic Agents	\$38,000	1997 – 1999
Renuka Pillutla	<i>P21/SIIR</i> , A <i>C-fos</i> Activator with Oncogenic Potential	\$38,000	1997 – 1999
Joanna Slusky	Summer	\$2,800	1997 – 1997
Robert Siegelbaum	Summer	\$2,800	1997 – 1997
Neal K. Moskowitz	Detailed Analysis of <i>Cdk2-p21</i> Interaction	\$25,000	1996 – 1998
Anju Dang	Elucidation of type 1 <i>IFN</i> : Receptor Interactions	\$43,000	1996 – 1998
Amanda Jetzt	Mechanistic Evolution of Acutely Transforming Retroviruses	\$25,000	1996 – 1996
William J. Kim	Summer	\$2,800	1996 – 1996
Eleanor Anne Carr-Schmid	Summer	\$2,800	1996 – 1996
Peter Sciavolino	Transcriptional Regulatory Properties Of <i>HoxB4</i>	\$20,000	1995 – 1997
Kelly M. Przybysz	<i>HMGI-C</i> in Growth and Transformation	\$38,000	1995 – 1996
Yanan Tian	Summer	\$2,800	1995 – 1995
Brian P. Pollack	Predocctoral	\$20,000	1994 – 1997
Catherine A. Schnabel	Predocctoral	\$20,000	1994 – 1997
Ravi D. Goel	Summer	\$2,800	1994 – 1997



Pre-, Post- and Summer Fellowships, 1988-2008

Clelia Biamonti	Predoctoral	\$20,000	1994 – 1995
Robert Laumbach	Summer	\$2,800	1994 – 1994
Michael Farrell	Replication Function of The <i>v-REL</i> Oncoprotein	\$20,000	1993 – 1996
Barrett N. Green	The Role of <i>IGFBP-5</i> In Tumorigenesis	\$20,000	1993 – 1996
Mary E. Northridge	Leukemia Mortality & Benzene Exposure: A Case –Control Study	\$38,000	1993 – 1995
Srijata Sarkar	Tumor Cell-Targeted Cytokine Gene Therapy of Cancer	\$38,000	1993 – 1995
Daniel B. Herz	Postdoctoral	\$38,000	1993 – 1995
Judith E. Bash	Characterization of c-REL-Effector Genes Affected in Human Lymphomas	\$20,000	1992 – 1994
Jeffrey Smith	Functional Analysis of Retroviral Integration Proteins	\$20,000	1991 – 1994
Robin Hammell	Molecular Mechanisms of Uncontrolled Growth of Renal Tubule Cells in Human Autosomal Dominant	\$20,000	1990 – 1993
Han-Mo Koo	Determination of Retroviral Mutation Rates	\$20,000	1990 – 1993
Jon Sharer	Role of the <i>mrc Operon</i> in Cell Division	\$20,000	1990 – 1993
Lisa Weis	Regulatory Mechanisms of the DNA B-polymerase Gene	\$20,000	1990 – 1993
Fred Mermelstein	Regulation of Transcription During Maturation of Leukemia Cells	\$38,000	1990 – 1993
Edward Yaskowiak	To Conduct a Genetic Analysis of Bacterial GTP-Binding Proteins	\$20,000	1989 – 1992
Maureen McKenzie	Study Nutrient Dependent Signalling	\$38,000	1989 – 1992
Yang-Ja Park	Immune Reaction to be Used to Halt Tumor Growth	\$38,000	1989 – 1992
Nancy Rak	The Biochemical Regulation of Genes At the Transcriptional Level	\$38,000	1989 – 1992
Janice B. Liesch	Postdoctoral	\$38,000	1988 – 1991
Geetha Muthkumaran	Postdoctoral	\$38,000	1988 – 1991
Dale G. Schaar	Predoctoral	\$20,000	1988 – 1991
Susan J. Muller	Predoctoral	\$20,000	1988 – 1991
Vincent Jung	Predoctoral	\$20,000	1988 – 1991
Tatiana M. Oberyszyn	Predoctoral	\$20,000	1988 – 1991

UMDNJ – SCHOOL OF OSTEOPATHIC MEDICINE

Michael Law, PhD	Transcription Factor Acetylation in Yeast	\$70,500	2007 – 2009
------------------	---	----------	-------------

Commission Members: Past & Present

MEMBER	TERM OF OFFICE	PROFESSIONAL AFFILIATION	AREA OF EXPERTISE
Kenneth Adler, MD, FACP	2004 – Present	Morristown Memorial Hospital	Hematology/Oncology
Ronald Altman, MD	1983 – 1988	Ex-Officio Member, DHSS	Cancer Epidemiology
Thomas Atherholt, PhD	1995 – Present	Ex-Officio Member, DEP	Environmental Sciences
Jeanne C. Beck, PhD	2004 – 2005	Coriell Institute	Molecular Biology
James Blumenstock	1997 – 1998	Ex-Officio Member, DHSS	Environmental Sciences
Eddy Bresnitz, MD, MS	1998 – 2008	Ex-Officio Member, DHSS	Cancer Epidemiology
James Broach, PhD	2004 – Present	Princeton University	Molecular Biology
Thomas Burke, PhD, MPH	1984 – 1986	Ex-Officio Member, DEP	Environmental Sciences
Frederick B. Cohen, MD	1983 – 2004	Newark Beth Israel Medical Center	Clinical Oncology
Lawrence Coia, MD	1997 – 2002	Community Medical Center	Radiation Oncology
Aldrage Cooper, Jr.	1984 – 1988	Johnson & Johnson	Public Affairs
Arnold Denton, PhD	1985 – 1987	Campbell Soup Company	Nutrition
George E. Dunaif, PhD	1989 – 2004	Campbell Soup Company	Nutritional Toxicology
Lynn Enquist, PhD	1995 – 2004	Princeton University	Molecular Biology
Elin Gursky, DSc	1995 – 1997	Ex-Officio Member, DHSS	Cancer Epidemiology
Zola Horovitz, PhD	1989 – 1995	Bristol-Myers Squibb Company	Technology Transfer & Scientific Planning
David Kaloupek	1984 – 1988	Hospital Corporation of America	Hospital Administrator
Barton A. Kamen, MD, PhD	2004 – Present	Leukemia & Lymphoma Society/ CINJ	Pediatric Hematology/ Oncology
Diana Lake, MD	1992 – 1995	New York Medical College	Clinical Oncology
Marie Leithauser, MBA, MS	2004 – Present	Bristol-Myers Squibb Company	Clinical Research
Arnold Levine, PhD	1985 – 1987	Princeton University	Molecular Oncology
James Orsini, MD	1990 – 1995	Clara Mass Medical Center	Clinical Oncology
Harvey L. Ozer, MD	2004 – 2008	NJMS/UMDNJ	Clinical Oncology
William Parkin, DVM, DrPH	1988 – 1995	Ex-Officio Member, DHSS	Cancer Epidemiology
Lindsey Pratt, MD	1983 – 1988	Newcomb Medical Center	Surgical Oncology
Barbara Rabinowitz, PhD, MSW, RN	1995 – 2009	Private Practice	Psychosocial Oncology
Stanley J. Robboy, MD	1987 – 1992	UMDNJ/NJMS	Cancer Pathology
Robert Simpson, PhD	1983 – 1994	Waksman Institute	Virology
Anna Marie Skalka, PhD	1983 – Present	Fox Chase Cancer Center	Molecular Oncology
Herbert E. Spiegel, PhD, MBA	1983 – 1995	Hoffmann-LaRoche	Clinical Biochemistry
Daniel Tripodi, PhD	1987 – 1989	Johnson & Johnson	Technology Transfer
Robert K. Tucker, PhD	1986 – 1995	Ex-Officio Member, DEP	Environmental Toxicology
Paul E. Wallner, DO, FACR	1988 – 2002	University of Pennsylvania	Radiation Oncology
Jeffrey Warren, MPA	1995 – Present	Park Davis Pharmaceuticals	Marketing

ADVISORY COMMITTEE ON EPIDEMIOLOGY/ENVIRONMENTAL CONTROL

Thomas Burke, PhD, MPH	NJ Department of Health & Senior Services	1987 – 1988
Richard Dime, PhD	NJ Department of Environmental Protection	1987 – 1988
Roy Fagin, MD, FACPM	The Port Authority of NY and NJ	1987 – 1988
Michael Gallo, PhD	UMD-RW Johnson Medical School	1987 – 1988
Michael Greenberg, PhD	Rutgers, The State University	1987 – 1988
Shirley Greene	The American Cancer Society	1987 – 1988
Joseph Highland	Princeton, New Jersey	1987 – 1988
Peter Kahn, PhD	Rutgers, The State University	1987 – 1988
Judith Klotz, DrPH	NJ Department of Health & Senior Services	1987 – 1988
Donald Lauria, MD	UMD-New Jersey Medical School	1987 – 1988
Lawrence Minert, MD, MPH	NJ Department of Health & Senior Services	1987 – 1988
Merry L. Morris, PhD	NJ Department of Environmental Protection	1987 – 1988
Reza Najem, PhD	UMD-New Jersey Medical School	1987 – 1988
Emil A. Pfitzer, PhD	Hoffman-La Roche, Inc.	1987 – 1988
Gloria Post, PhD	NJ Department of Environmental Protection	1987 – 1988
John Slade, MD	Saint Peter's Medical Center	1987 – 1988
Robert Snyder, PhD	Rutgers, The State University	1987 – 1988
Michael Utidjian, MD	American Cyanamid	1987 – 1988
Bonnie Wiseman, MPH	NJ Department of Health & Senior Services	1987 – 1988
Dr. Nicholas Wright	UMD-RW Johnson Medical School	1987 – 1988

ADVISORY COMMITTEE ON RADIATION ONCOLOGY

Alan Appleby, PhD	Rutgers, The State University	1988 – 1990
Helene Z. Hill, PhD	UMD-New Jersey Medical School	1986 – 1990
Roger Howell, PhD	UMD-New Jersey Medical School	1988 – 1990
Louis Sanfilippo, MD	Saint Barnabas Medical Center	1986 – 1990
K. David Steidley, PhD	Saint Barnabas Medical Center	1986 – 1990
Jed Waldman, PhD	UMD-RW Johnson Medical School	1988 – 1990
Paul E. Wallner, DO	Cooper Hospital/University Medical Center	1986 – 1990
Lewis Zieger, MD	Cooper Hospital University Medical Center	1988 – 1990

BASIC CANCER RESEARCH ADVISORY GROUP

David Axelrod, PhD	Waksman Institute	1986 – 1991
Ragvir Athwal, PhD	Coriell Institute for Medical Research	1991 – 1993
Subal bishayee, PhD	Coriell Institute for Medical Research	1991 – 1998
Suzie Chen, PhD	Rutgers, The State University	1997 – Present
Ted Cox, PhD	Princeton University	1987 – 1990
David Denhardt, PhD	Rutgers, The State University	1991 – 1999
Giampiers di Mayorca, MD	UMD-New Jersey Medical School	1986 – 1987
S.J. Flint, PhD	Princeton University	1994 – 1997
David Gold, PhD	Garden State Cancer Center	1997 – Present
Marian L. Harter, PhD	UMD-New Jersey Medical School	1987 – 1988
Marie Hoover, PhD	Coriell Institute for Medical Research	1997 – Present
Masayori Inouye, PhD	UMD-RW Johnson Medical School	1994 – 1995
Daniel F. Klessig, PhD	Waksman Institute	1987 – 1993

Commission Advisory Groups - Past and Present Members

Jeffrey D. Laskin, PhD	UMD-RW Johnson Medical School	1986 – 1993
Arnold J. Levine, PhD	Princeton University	1986 – 1987
Alice Y.-C Liu, PhD	Rutgers, The State University	1990 – Present
Leroy Liu, PhD	UMDNJ-RW Johnson Medical School	1994 – 1998
Gerard J. McGarrity, PhD	Coriell Institute for Medical Research	1986 – 1991
Ronald Morris, MD	UMD-RW Johnson Medical School	1989 – 1991
Harvey L. Ozer, MD	UMD-New Jersey Medical School	1994 – 1995
Nicholas M. Ponzio, PhD	UMD-New Jersey Medical School	1987 – 1991
Edith Postel, PhD	Princeton University	1997 – Present
Arnold Rabson, MD	CABM	1994 – 1997
Elizabeth Raveche, PhD	UMD-New Jersey Medical School	1994 – Present
Alan S. Rosenthal, MD	Boehringer Ingelheim Pharmaceuticals	1986 – 1987
R. Walter Schlesinger, MD	UMD-RW Johnson Medical School	1986 – 1989
Edward M. Scholnick, MD	Merck Sharp & Dohme	1987 – 1988
Michael I. Sherman, PhD	Hoffman LaRoche	1987 – 1993
Michael Small, PhD	UMD-New Jersey Medical School	1994 – 1998
Ian Whitehead, PhD	UMDNJD-New Jersey Medical School	1999 – Present
Nancy Woychik, PhD	RWJ Medical School	1997 – Present
Chung S. Yang, PhD	Rutgers, The State University	1991 – 1998
Jonathan Yavelow, PhD	Rider University	1997 – Present

BREAST CANCER RESEARCH ADVISORY GROUP

David August, MD	The Cancer Institute of New Jersey	1995 – 1999
David Axelrod, PhD	Rutgers, The State University	2006 – Present
Cynthia G. Ayres, PhD	The American Cancer Society	2004 – Present
Linda Basilio	Wallburg, New Jersey	1998 – Present
Arnold Baskies, MD	Rancocas Hospital	1998 – 2001
Jeanne Beck, PhD	Coriell Institute for Medical Research	1995 – 2006
Patrick K. Bender, PhD	Coriell Institute for Medical Research	2006 – Present
Kat Block	Springfield, New Jersey	2001 – Present
Donna Bocco	The American Cancer Society	1996 – 1999
Eileen Bova	The American Cancer Society	1998 – 1999
Margaret Bryan, MD	UMDNJ-New Jersey Medical School	1997 – Present
Wendy Budin, PhD, RN	New York University Medical Center	2004 – Present
Deborah M. Capko, MD	Hackensack Medical Center	1997 – Present
Evelyn Dries	The American Cancer Society	2000 – 2001
Generosa Grana, MD	Cooper Cancer Institute	1995 – Present
The Honorable Rose Marie Heck	Assemblywomen, District 38	1995 – 2004
Randi E. Issacs, MD	Hackensack Medical Center	1995 – 1996
Erika Jurasita, DO	Hickory Run Family Practice	1995 – 1997
Thomas Kearney, MD	The Cancer Institute of New Jersey	1999 – 2005
Judi Mason Klein	New Brunswick, New Jersey	1995 – Present
Betsy Kohler, MPH	NJ Department of Health & Senior Services	1995 – 2008
Reju Korah, PhD	Monmouth Medical Center	2001 – 2003
Joyce Maso	Skillman, New Jersey	1995 – Present
Gilbert Melnick, MD	The American Cancer Society	1995 – 1996



Commission Advisory Groups - Past and Present Members

Isadore M. Pike, MD	Bristol-Myers Squibb	1995 – 1997
Lyn Ransom, D.M.A.	Lambertville, NJ	2007 – Present
Michael Reiss, MD	The Cancer Institute of New Jersey	2001 – Present
Helen Richards	Caring at Columbia University	1998 – Present
Susan Rittling, PhD	Rutgers, The State University	1995 – 2005
Carmel Rutman	Paramas, New Jersey	2002 – Present
Janet B. Schoenberg, MPH	NJ Department of Health & Senior Services	1995 – 1996
Eva Sciandra	The American Cancer Society	2000 – Present
Adria Sherman, PhD	Rutgers, The State University	1995 – 1997
Thomas J. Smith, MD	Morristown Memorial Hospital	1999 – 2003
Mary Storms	Bristol-Myers Squibb	1999 – Present
Gail Thomas, MD, PhD	Monmouth Medical Center	1995 – 1996
Carin Uphill	The American Cancer Society	1999 – 2000
Susan Villapiano	Wayside, New Jersey	1995 – 1997
Dorothy Marie Wahlers	The American Cancer Society	2002 – Present
Barbara Waters	The Susan G. Komen Foundation	2002 – Present
Paul E. Wallner, DO	University of Pennsylvania	1995 – 1999
Robert Weider, MD, PhD	UMDNJ-New Jersey Medical School	1995 – Present
Jeffrey Wenger, MD	Cooper Hospital/University Medical Center	1995 – 1999

CANCER CONTROL AND PREVENTION ADVISORY GROUP

Susan Ackerman, PhD, MA	Response Analysis	1994 – 1995
Norma Almanza	The YA Group, Inc.	2001 – Present
Gilbert Baez	Jersey City, NJ	2000 – Present
Elisa Bantera	Rutgers, The State University	2000 – Present
Adrienne Bendich, PhD	Hoffman-LaRoche	1994 – 1995
Thomas Burke, PhD, MPH	NJ Department of Health & Senior Services	1987 – 1989
Gayle Cornish	The Cancer Institute of New Jersey	1997 – 2005
Richard Dime, PhD	NJ Department of Env. Protect & Energy	1987 – 1989
Kathleen Jennings-Dozier	MCP Hahnemann University	2000 – 2002
Andrew Farkas, PhD	Rutgers, The State University	1997 – 2000
Roy Fagin, MD, FAPM	Port Authority of NY & NJ	1987 – 1991
William Feyerweather, DrPH	DeNenorus & Company	1991 – 1992
Jose Gallo, PhD	The Cancer Institute of New Jersey	1995 – 1996
Michael Gallo, PhD	UMD-RW Johnson Medical School	1994 – 1995
Generosa Grana, MD	Cooper Hospital/University Medical Center	1994 – Present
Michael Greenberg, PhD	Rutgers, The State University	1987 – 1992
Shirley Greene	American Cancer Society	1988 – 1990
Marilyn Hansen, CTR	NJ Operations Cancer Program	1995 – Present
Debra Harlan, MPH	NJ Department of Health & Senior Services	1994 – 1995
David Henry, MPH	Montgomery Township Health Department	1997 – Present
George Hill, MD	UMD-New Jersey Medical School	1995 – 2000
Shawna Hudson, PhD	The Cancer Institute of New Jersey	2001 – Present
Jun-Yan Hong, PhD	UMDNJ-NJ Medical School	2000 – Present
Peter Kahn, PhD	Rutgers, The State University	1988 – 1990
Judith Klotz, DrPH, EDPS	NJ Department of Health & Senior Services	1987 – Present

Commission Advisory Groups - Past and Present Members

Betsy A. Kohler, MPH	NJ Department of Health & Senior Services	1991 – 2000
Donald Lauria, MD	UMD-New Jersey Medical School	1988 – 1990
Pauline Lenhardt, RN	NJ Department of Health & Senior Services	1991 – 1993
Susan Levin	Lung Cancer Circle of Hope	2005 – Present
Jane Lewis, DrPH	UMD-RW Johnson Medical School	1997 – Present
Cari Miller	The Peer Review Organization of NJ	2000 – Present
Lawrence Minert, MD, MPH	NJ Department of Health & Senior Services	1987 – 1989
Merry L. Morris, PhD	NJ Department of Env. Protection & Energy	1987 – 1990
Rachelle Munic, PA	Cooper Hospital/University Medical Center	1994 – 1995
Resa Najem, MD, PhD	UMD-New Jersey Medical School	1994 – 1995
William Nicholson, DrPH	Mt. Sinai Medical Center	1994 – 1995
Rebecca T. Parkin, PhD, MPH	Beccam Services	1994 – 1995
William E. Parkin, DVM, DrPH	NJ Department of Health & Senior Services	1988 – 1992
Emil A. Pfitzer, ScD	Hoffman-La Roche, Inc.	1994 – 1995
Nancy Pinken, PhD	East Brunswick, NJ	1995 – 2001
Gloria Post, PhD	NJ Department of Env. Protection & Energy	1987 – 1989
Mitch Rosen	EOSHI	2000 – Present
Dona Schneider, PhD, MPH	Rutgers, The State University	1992 – Present
Ian Schoenberg, MPH	NJ Department of Health & Senior Services	1991 – 1993
Donald Shapiro, MD	UMDNJ	1994 – 1995
John Slade, MD	Saint Peters Medical Center	1990 – 1995
Robert Snyder, PhD	Rutgers, The State University	1987 – 1988
Annette Stemhagen, DrPH	Merck & Company	1994 – 1995
Robert K. Tucker, PhD	NJ Department of Env. Protection & Energy	1988 – 1992
Michael Utidjian, MD	American Cyanamid	1987 – 1989
Bonnie Wiseman, MPH	NJ Department of Health & Senior Services	1987 – 1992
Chung S. Yang, PhD	Rutgers, The State University	1997 – 2000
Nicholas Wright, MD	UMD-RW Johnson Medical School	1988 – 1990

COOPERATIVE ONCOLOGY GROUP OF NEW JERSEY

Doreen Babott, MD	The Medical Center at Princeton	1988 – 1992
Arnold M. Baskies, MD	Rancocas Valley Surgical Associates	1988 – 1992
Donald K. Brief, MD	Newark Beth Israel Medical Center	1988 – 1989
David Blom, DO	Vineland, New Jersey	1988 – 1990
Eugene Cheslock, MD	Riverview Medical Center	1988 – 1990
Frederick B. Cohen, MD	Newark Beth Israel Medical Center	1988 – 1992
Burton Garfinkle, MD	Christ Hospital	1988 – 1991
Ralph Steven Greco, MD	UMD-RW Johnson Medical School	1988 – 1992
George James Hill, MD	UMD-New Jersey Medical School	1988 – 1992
Robert V.P. Hutter, MD	Saint Barnabas Medical Center	1988 – 1992
Lewis J. Kampel, MD	Middlesex Oncology, PA	1989 – 1992
Alan J. Lippman, MD	Newark Beth Israel Medical Center	1988 – 1992
Steven William Papish, MD	Morristown Memorial Hospital	1988 – 1992
Henry Rosin, MD	Midland Park, New Jersey	1988 – 1992
William A. Sweeney, MD	St. Peter's Medical Center	1988 – 1992
Paul E. Wallner, DO	University of Pennsylvania	1988 – 1992



Commission Advisory Groups - Past and Present Members

EDUCATIONAL SUBCOMMITTEE

Michael Greenberg, PhD	Rutgers, The State University	1988 – 1989
Michael B. Harris, MD	Hackensack Medical Center	1988 – 1989
George J. Hill, MD	UMD-New Jersey Medical School	1988 – 1989
Helen Z. Hill, PhD	UMD-New Jersey Medical School	1988 – 1989
W. Clark Lambert, MD, PhD	UMD-New Jersey Medical School	1988 – 1989
Elaine Millner, DrPH	The Cancer Institute of New Jersey	1988 – 1989
Nicholas M. Ponzio, PhD	UMD-New Jersey Medical School	1988 – 1989
Herbert E. Spiegel, PhD	NJ Commission on Cancer Research	1988 – 1989

JOINT NURSING/PSYCHOSOCIAL ADVISORY GROUP

Denyse Adler, MA	The Adler Group	1990 – Present
Frances Cartwright-Alcarese PhD, RN,AOCN	Mt. Sinai Hospital	2004 – 2006
Maureen Alex, RN	The American Cancer Society	1986 – 1987
Alan Axelrod, MSW	Princeton HealthCare System	1996 – Present
Cynthia Ayres, PhD, RN	Rutgers, The State University	2006 – Present
Patricia Moffa Barse, RN, MSN,AOCN	Cooper Health Systems	1996 – 1999
Donna Bocco	The American Cancer Society	1996 – 2004
Rev. David M. Bossman, PhD	Seton Hall University	1986 – 1989
Susan J. Brown, RN, MSN	Marlton, New Jersey	1986 – 1990
Wendy Budin, PhD, RNC-BC	New York University Medical Center	1994 – Present
Diane Byrns-Paul, MS, RN	St. Elizabeth’s Medical Center	1994 – 1997
Patricia Carver, PhD	Princeton, New Jersey	1994 – 1997
Elizabeth Clark, PhD, MPH	NCCS	1986 – 1993
Susan Orkand Cohen, MA,ADTR	Tomorrows Children’s Institute	1986 – 2002
Regina Cunningham, MA, RN	The Cancer Institute of New Jersey	1994 – 1997
Jayne M. Craig, MS,RN,C,CS	Somerset Medical Center	1999 – 2001
Dr. Dorothy DeMaio	Rutgers College of Nursing	1986 – 1989
John R. deVelder	RWJ University Hospital	1999 – 2004
Alice Renick Ettinger, RN,MSN,CPNP	UMD-RW Johnson Medical School	1987 – 2004
Julie Fitzgerald, PhD	Kean University	2008 – Present
Denise C. Fyffe, PhD	Kessler Foundation Research Center	2006 – Present
David Gordon, MS	Living Through Learning Foundation	2001 – Present
Elsie E. Gulick, PhD, RN	Rutgers, The State University	1986 – 1989
Phyliss Shanley-Hansell, RN	Seton Hall University	1986 – 1989
Joanne D. Hayes, MA, RN	The Nexus Group	1992 – 1995
Gail A. Hilbert, DNSc, RN	The College of New Jersey	1989 – 1991
Ann F. deJong Hodgson, RN	Nutley, New Jersey	1987 – 1992
Barbara Hoffman, JD	Cranbury, New Jersey	1988 – 1991
Shirley Hwang, RN, MS	East Orange VA Medical Center	1994 – 1999
Linda Kennelly, MA,RN,OCN	Annadel, New Jersey	1994 – 1995
Larissa Labay, Psy.D	Tomorrows Children’s Institute	2002 – 2006
Kathy Leifeste, RN, MSN	Overlook Hospital	2008 – Present
Elise Lev, PhD, RN	Rutgers, The State University	1992 – 1993
Ellen Levine, MSW, LCSW	The Wellness Community of Central NJ	2002 – Present

Commission Advisory Groups - Past and Present Members

Ruth Lin, RN, MS, AOCN	Morristown Memorial Hospital	2002 – Present
Lois Lorenz, LCSW, Eds	The American Cancer Society	2001 – 2004
Debra Mashberg, PhD, RN	Memorial Sloan-Kettering	1988 – 1991
Suzzane Maggiore, MSW	Department of Veteran Affairs Medical Ctr.	1994 – 1995
Elaine S. Millner, DrPH	Fort Lee, New Jersey	1986 – 1991
Leah Mraz, BSN, RN, OCN	The Cancer Institute of New Jersey	2003 – 2004
Judith Much, RN	The Cancer Institute of New Jersey	1997 – 2004
Kathleen Neville, PhD, RN	Kean College of Nursing	1994 – Present
Mildred Ortu-Kowalski, PhD, RN	Novartis Oncology	1999 – Present
Diane Outcault, RN, BS	St. Elizabeth Medical Center	1992 – 1993
Lissa Parsonnet, PhD	Private Practice	1994 – Present
Linda J. Patrick-Miller, PhD	The Cancer Institute of New Jersey	2000 - Present
Barbara Rabinowitz, PhD	Lakewood, New Jersey	1986 – 2008
Barbara Rainear, RN, MSW	Cooper Hospital/University Medical Center	1993 – 1999
Peggy A. Rothbaum, PhD	Westfield, New Jersey	1994 – 1999
Nelda Samorel, EdD, RN	William Paterson University	1992 – 1993
Rev. Robert Starling-Meyer	Seton Hall University	2003 – 2004
Alexander Thomson, ACSW	Hackensack Cancer Center	1994 – 1995
Gary A. Walco, PhD	Tomorrows Children's Institute	1993 – 2001
Kathleen Walsh Scura, EdD, RN, GNPC	Rutgers, The State University	2000 – Present
Martha Weiner, MS, RN	Cooper Cancer Institute	2000 – 2002
Carole S. Zawid, PhD, RN	Shore Memorial Medical Center	1992 – 1994

MULTIDISCIPLINARY CLINICAL ADVISORY GROUP

Kenneth Adler, MD	Morristown Memorial	1994 – 1995
Steven Adler, MD	Denville, New Jersey	1994 – 1995
Umar Atabek, MD	Cooper University/Medical Center	1994 – 1995
Hugh Auchincloss, MD	Ridgeway, New Jersey	1987 – 1988
Doreen Babott, MD	The Medical Center at Princeton	1992 – 1995
Arnold Baskies, MD	Rancocas Medical Association	1988 – 1992
John Bauman, MD	The Medical Center at Princeton	1994 – 1995
David Blom, DO	Vineland, New Jersey	1988 – 1989
Donald Brief, MD	Newark Beth Israel Medical Center	1988 – 1993
Eugene Cheslock, MD	Riverview Medical Center	1988 – 1991
Fredrick B. Cohen, MD	Newark Beth Israel Medical Center	1994 – 1995
Robert L. DeJager, MD	UMD-New Jersey Medical School	1987 – 1988
Louis G. Fares, MD	Trenton, New Jersey	1987 – 1988
Burton Garfinkel, MD	Christ Hospital	1988 – 1991
Jock Goldberg, MD	Cooper Hospital/University Medical Center	1994 – 1995
Michael I. Goldberg, MD	UMD-RW Johnson Medical School	1986 – 1988
Robert M. Goldberg, MD	Somers Point, New Jersey	1986 – 1988
David M. Goldenberg, MD, ScD	Garden State Cancer Center	1987 – 1988
Ralph Greco, MD	UMD-RW Johnson Medical School	1986 – 1992
George James Hill, MD	UMD- New Jersey Medical School	1992 – 1995
Robert V.P. Hutter, MD	Saint Barnabas Medical Center	1986 – 1988
Elizabeth Johnson, MD	Cooper Hospital/University Medical Center	1994 – 1995



Commission Advisory Groups - Past and Present Members

Lewis J. Kampel, MD	Middlesex Oncology	1993 – 1994
Allan Lippman, MD	Newark Beth Israel Medical Center	1986 – 1993
Richard A. Michaelson, MD	Saint Barnabas Medical Center	1986 – 1988
Michael Nissenblatt, MD	UMD-RW Johnson Medical School	1986 – 1988
Steven Papish, MD	Morristown Memorial Hospital	1987 – 1992
Abraham Risk, MD	Morristown Memorial Hospital	1986 – 1988
Richard J. Rosenbluth, MD	Hackensack Medical Center	1994 – 1995
Henry Rosin, MD	Valley Hospital	1988 – 1992
Arnold D. Rubin, MD	Paterson, New Jersey	1994 – 1995
Benjamin F. Rush, Jr., MD	UMD-New Jersey Medical School	1987 – 1988
David Sharon, MD	Monmouth Medical Center	1994 – 1995
William Sweeney, MD	Saint Peter's Medical Center	1987 – 1992
Erwin Tepper, MD	Monmouth Medical Center	1994 – 1995
Paul E. Wallner, DO	Cooper Hospital/University Medical Center	1992 – 1995

PEDIATRIC HEMATOLOGY ONCOLOGY NETWORK OF NJ

Linda Ader, MSW	Tomorrows Children's Institute	1997 – 2001
Burton Appel, MD	Tomorrows Children's Institute	1997 – 2002
Justiniano F. Bagtas, MD	Monmouth Medical Center	1995 – 2002
Barry L. Barnoski, PhD	Cooper Hospital/University Medical Center	1997 – 2002
Wondwesson Bekele, MD	Newark Beth Israel Medical Center	1987 – 2002
Mary Ann Bonilla, MD	Saint Barnabas Medical Center	1997 – 2001
Frederick C. Braun, Jr., MD	Overlook Hospital	1987 – 2001
Joel A. Brochstein, MD	Tomorrows Children's Institute	1991 – 2002
Christine Call Sternberg, MAT/MTC	Robert Wood Johnson University Hospital	1997 – 2001
Hope Castoria, RN, BS, CPON	Tomorrows Children's Institute	1997 – 2001
Mary Connell, CRA	Tomorrows Children's Institute	1997 – 2001
Paola Conte, PhD	Tomorrows Children's Institute	2002 – 2003
Carlie Cord, RN, BS, CPON	Tomorrows Children's Institute	1997 – 2001
Ann Marie DeMarco, CPNP	Newark Beth Israel Medical Center	1997 – 2001
Frank Desposito, MD	Children's Hospital of New Jersey	1994 – 1996
Steven Diamond, MD	Tomorrows Children's Institute	1990 – 2002
Milton Donaldson, MD	Cooper Hospital/University Medical Center	1994 – 1997
Richard Drachtman, MD	Robert Wood Johnson University Hospital	1991 – 2002
Alice Ettinger, RN, CPNP	St. Peter's Medical Center	2002 – 2003
Lawrence J. Ettinger, MD	St. Peter's Medical Center	1986 – Present
Shari Feinberg, RN, CRA	Newark Beth Israel Medical Center	1997 – 2001
Lucia Figueroa, MSW	Tomorrows Children's Institute	1997 – 2001
Linda Ficher Hopkins, LCSW	Monmouth Medical Center	1997 – 2001
Frances Flug, MD	Tomorrows Children's Institute	1991 – 2002
Pauline Garcia, CSW	Newark Beth Israel Medical Center	1997 – 2001
Alfred Gillio, MD	Tomorrows Children's Institute	1997 – 2002
Barbara H. Greenbaum, MD	The Children's Hospital of Philadelphia	1987 – 2002
John Gregory, MD	Tomorrows Children's Institute	2002 – 2003
Laura Goode, RN, RNC	Tomorrows Children's Institute	1997 – 2001
Sunanda Gaur, MD	Robert Wood Johnson University Hospital	1990 – 2001

Commission Advisory Groups - Past and Present Members

Steven Halpern, MD	Tomorrows Children's Institute	1987 – 2002
Paul Harlow, MD	Tomorrows Children's Institute	2002 – 2003
Michael B. Harris, MD	Tomorrows Children's Institute	1987 – Present
Lateefah T. Hayes, CSW	The Children's Hospital of Philadelphia	1997 – 2001
Rod J. Herrera, LCSW, MSW	Cooper Hospital/University Medical Center	1997 – 2001
Ann Marie Hill, MBA	NJ Commission on Cancer Research	1997 – 2001
Kenneth Hirsch, MD	Cooper Hospital/University Medical Center	1992 – 1996
Peter Y. Ho, MD	Jersey Shore Medical Center	1995 – 2002
Emy Hyans, MA, SW	Tomorrows Children's Institute	1997 – 2001
Vijay V. Joshi, MD, PhD	Children's Hospital of New Jersey	1987 – 1991
Peri Kamalakar, MD	Newark Beth Israel Medical Center	1986 – Present
Barton Kamen, MD	Robert Wood Johnson University Hospital	2003 – Present
Eric Kramer, MD	Cooper Hospital/University Medical Center	1991 – 1992
Christine Kurtz, PNP	Monmouth Medical Center	1997 – 2001
Larissa Labay, Psy.D	Tomorrows Children's Institute	2002 – 2003
Carol Lehan, MD	Monmouth Medical Center	1990 – 1991
Cathy Lepniotis, RN	Robert Wood Johnson University Hospital	1997 – 2002
Hazem Mahmoud, MD	Overlook Hospital	2003 – Present
David Mandelbaum, MD	Robert Wood Johnson University Hospital	1994 – 2001
Michael B. Marchildon, MD	Cooper Hospital/University Medical Center	1986 – 1989
Ellen Mass, RN, MSN	Tomorrows Children's Institute	1997 – 2001
Margaret Masterson, MD	Jersey Shore Medical Center	1995 – Present
Sherri Mayans, RN, MSN	Tomorrows Children's Institute	1997 – 2001
Maureen Mazzaccaro, Rn, MS	Jersey Shore Medical Center	1997 – 2001
J. Phil McCoy, PhD	Cooper Hospital/University Medical Center	1994 – 2002
Lydia McMorro, PhD	Cooper Hospital/University Medical Center	1994 – 1996
Kevin McSherry, MD	Newark Beth Israel Medical Center	1990 – 2001
Bernard J. Member, MD	UMD-RW Johnson Medical School	1987 – 1991
Michelle Miller, MD	Overlook Hospital	2002 – 2003
Susan Murphy, MD	Saint Barnabas Medical Center	1991 – 2002
Ann G. Nepo, MD	Saint Barnabas Medical Center	1987 – Present
Pathma Nelson, MD	Cooper Hospital/University Medical Center	1989 – 1992
Renee Nigam, MD	Robert Wood Johnson University Hospital	1997 – 2002
W. Roy Overton, PhD	Cooper Hospital/University Medical Center	1997 – 2002
James Oleske, MD, MPH	UMD-New Jersey Medical School	1986 – 1987
Steven Paul, MD	Cooper Hospital/University Medical Center	1997 – Present
James Powell, MD	Overlook Hospital	2002 – 2003
Digna Quiles, LPN, CCRA	Cooper Hospital/University Medical Center	1997 – 2001
Noreen Qutten, RN,MA,CPNP, CPON	Tomorrows Children's Institute	1997 – 2001
Alice Renick-Ettinger, RN, CPNP	St. Peter's Medical Center	1997 – 2002
Carina Rodriquez, RN	Newark Beth Israel Medical Center	1997 – 2001
Tracey Rojek, RN, CNS	Tomorrows Children's Institute	1997 – 2001
Joan Rubin, CPON, CRA	Robert Wood Johnson University Hospital	1997 – 2002
Beverly R. Ryan, MD	Tomorrows Children's Institute	1987 – 2002
Priscilla Scheiner, ACSW	Robert Wood Johnson University Hospital	1997 – 2001
Dona Schneider, PhD, MPH	Rutgers, The State University	1997 – Present



Commission Advisory Groups - Past and Present Members

Edward Schultz, PhD	Newark Beth Israel Medical Center	1994 – 2001
Richard Sills, MD	Saint Barnabas Medical Center	1990 – 2001
Annette Sinski, RN, CNS	Tomorrows Children's Institute	1997 – 2001
Brenda C. Sison, MD	Saint Barnabas Medical Center	1990 – 2002
Carol Smyth, RN MS,OCN,CPON	Tomorrows Children's Institute	1997 – 2001
Judy Solomon, MSW, MPH	Tomorrows Children's Institute	1997 – 2001
Stacey Springer, MSW	Newark Beth Israel Medical Center	1997 – 2001
Cindy S. Steele, MD	Tomorrows Children's Institute	1987 – 2002
Steven Stowe, MD	UMD-New Jersey Medical School	1986 – 1987
Timur Sumer, MD	UMD-New Jersey Medical School	1987 – 1991
Joanne Szymanski, RN, CPON	Monmouth Medical Center	1987 – 2001
Bruce Terrin, MD	Tomorrows Children's Institute	2002 – 2003
Steven Thompson, MD	Tomorrows Children's Institute	2002 – 2003
Cheryl Sterling, PhD	Tomorrows Children's Institute	2002 – 2003
Susan F. Travis, MD	The Children's Hospital of Philadelphia	1987 – Present
Gary Walco, PhD	Tomorrows Children's Institute	1997 – 2002
Thomas R. Walters, MD	UMD-New Jersey Medical School	1987 – 1991
Michael A. Weiner, MD	Hackensack Medical Center	1994 – 1996
Jeffrey S. Wenger, MD	Cooper Hospital/University Medical Center	1987 – 1991
Thomas Whalen, MD	Cooper Hospital/University Medical Center	1989 – 1992
James A. Wolff, MD	Overlook Hospital	1986 – 1992
Ann Zanelli, RN	Overlook Hospital	1995 – 2001

PROSTATE CANCER RESEARCH ADVISORY GROUP

H. Robert Carter	Little Silver, NJ	1998 – 2004
Keith DeCosta	West Essex Medical Center	1998 – 2004
Robert DiPaola, MD	The Cancer Institute of New Jersey	1998 – 2004
Peter Doherty	Morristown, NJ	1998 – 2004
Thea Greco	Roseland, NJ	1998 – 2004
Christopher Koprowski, MD	Cooper Health System	1998 – 2000
Stuart Leitner, MD	Saint Barnabas Health Care System	1998 – 2004
Michael Perrotti, MD	UMDNJ-RWJMS	1999 – 2004
Don Reed	Hopewell, NJ	1998 – 2002
George Rhoads, MD, MPH	EOSHI	1998 – 2004
Terry Roe	US TOO!	1999 – 2004
Cory Abate Shen, PhD	Center for Advanced Biotech. & Med.	1998 – 2004

CELEBRATING
25 Years of
Excellence

*Section 2:
2008 Annual Report*



The overall objectives, strategies and priorities of the NJCCR are set by the Commissioners, who actively participate in overseeing the program and make

final recommendations on the research projects to be funded. In each Grant Cycle, the NJCCR awards grants based on the member's recommendations, following peer reviewer's evaluations, assessment of responsiveness to program priorities, and available funds.

The NJCCR currently consists of eight members appointed by the Governor with the consent of the Senate: four scientists/clinicians; one member from a non-profit health organization, one member from private industry; one ex-officio member from the Department of Health and Senior Services, and one ex-officio member from the Department of Environmental Protection.

Anna Marie Skalka, Ph.D. - Chairperson

Dr. Skalka is Professor and Basic Science Director Emeritus at the Fox Chase Cancer Center in Philadelphia. Previously, she chaired the Department of Molecular Oncology at the Roche Institute for Molecular Biology in Nutley. Dr. Skalka has served on a number of national and international scientific advisory committees, and on the editorial boards of several scientific journals. She was a recipient of an Outstanding Investigator Grant from the National Cancer Institute and an unrestricted grant for research in infectious diseases from the Bristol Myers Squibb Co. In 1994, in recognition for her outstanding achievements, Dr. Skalka was elected a Fellow of the American Academy of Arts and Sciences and in 1996 she was elected to the American Association for the Advancement of Science and the American Academy of Microbiology (AAM), serving on the Board of Governors from 1999-2002. In 2008, she was recognized as one of the state's Outstanding Women in Science by the NJ Association for Biomedical Research, and she also received the Scientific Research Award from the American Cancer Society, PA Division. Dr. Skalka is an internationally recognized expert on molecular genetics and the molecular biology of RNA tumor viruses. Together with former Commissioner Dr. Lynn Enquist, she is coauthor of the leading virology textbook. Dr. Skalka resides in Princeton, New Jersey.

Kenneth R. Adler, M.D., FACP - Vice Chairman

Dr. Kenneth Adler is currently an attending physician in Hematology-Oncology at Morristown Memorial Hospital and an assistant clinical professor at the University of Medicine and Dentistry of New Jersey. He attended the University of Pittsburgh and graduated from Albany Medical College in New York. In addition, his internal medicine residency and Hematology-Oncology fellowship was completed at Albany Medical Center. In 2002, Dr. Adler was awarded the American Cancer Society of St. George National Award for his volunteer work on the local, state, and national level. He has served as a volunteer of the American Cancer Society since 1981 and has served on the National Oversight committee for

the I Can Cope national program and chaired the state committee for patient and family services. He is active on the board of Cancer Hope Network and Gilda's Club and serves on the medical advisory board of the Susan G. Komen Foundation. Dr. Adler was recently appointed to the National Clinical Practice Committee of the American Society of Hematology. Furthermore, Dr. Adler has been recognized as one of the leading oncologists/hematologists in the Metropolitan New York/New Jersey area, in the Castle-Conolly Top Doctors in the Northeast Region and has also been named in *New Jersey Monthly* for the past eight years. He was named Physician of the Year by the American Cancer Society, and was honored by the New Jersey State Assembly for this award. He also received the Physician Home Care Award for Somerset County and was honored at the 2003 Pink Tie Ball by the Susan G. Komen Foundation of Northern New Jersey for his care of women with breast cancer. Dr. Adler was honored to receive the Community Service Award from the VNA of Northern New Jersey in 2004. He recently wrote and helped edit the introduction to the book *I'm Sorry You Have to Be Here*, by his patient Lois Cappetta-Bhatt, a mother's story on cancer, family, and support. In December, 2006 Dr. Adler received the American Society of Hematology National Public Service Award for the work he did on Pay-for-Performance for the society.

Thomas Atherholt, Ph.D.

Dr. Atherholt is a member of the Office of Science of the New Jersey Department of Environmental Protection (DEP) where he is a research microbiologist. Dr. Atherholt received his doctorate in microbiology from Rutgers University. He performed environmental research at the Coriell Institute for Medical Research in Camden, NJ prior to joining the DEP in 1990. Dr. Atherholt serves as an ex-officio member representing the Commissioner of the Department of Environmental Protection. He was awarded a Professional Achievement Award by the State of New Jersey for award-winning drinking water research. He resides in Moorestown, New Jersey.

James Broach, Ph.D.

Dr. Broach is currently serving as Associate Director of the Lewis-Sigler Institute for Integrative Genomics and Professor and Associate Chair of the Department of Molecular Biology at Princeton University. He completed his undergraduate studies at Yale University and was awarded a Bachelor of Science degree in Chemistry in 1969. In 1973, he was awarded a Ph.D. in Biochemistry from the University of California, Berkeley, where he also completed his Predoctoral fellowship in Biochemistry, and Postdoctoral Fellowship in Medical Physics. In addition, he completed a Postdoctoral Fellowship and was subsequently employed as a Staff Scientist at Cold Spring Harbor Laboratory. He then joined the State University of New York at Stony Brook as an Assistant/Associate Professor, a position he held just prior to serving in his current position at Princeton University. Dr. Broach served on the Scientific Review Board of the Frederick Cancer Center of the National Cancer Institute and has served as a member of both the Genetics and the Genomics Study Sections and Chair of and Genomics, Computational

Biology and Technology Study Section of the National Institutes of Health. He was Co-Founder and Director of Research for Cadus Pharmaceuticals and sits on the Board of Directors of Cadus Corporation. He also served as Editor for the Journal *Molecular and Cellular Biology* and Associate Editor for the Journal *Cell*. Dr. Broach is a Fellow of the American Academy of Microbiology and the Co-Director and Review Board Member of the Life Sciences Research Foundation. Dr. Broach is also a Trustee of the University of Medicine and Dentistry of New Jersey. He has published more than 150 articles in the area of molecular biology and holds a number of patents in drug discovery technologies.

Barton A. Kamen, M.D., Ph.D.

Dr. Kamen is the Executive Vice President and Chief Medical Officer of the Leukemia & Lymphoma Society. In addition, Dr. Kamen also serves as a Professor of Pediatrics and Pharmacology at the Cancer Institute of New Jersey, Robert Wood Johnson Medical School, New Brunswick, NJ. He received his M.D. and Ph.D. from Case Western Reserve University, Cleveland, OH, and served his residency and fellowship in pediatrics and pediatric hematology/oncology and pharmacology at Yale University, New Haven, CT. Dr. Kamen spent three years in Wisconsin and then more than 15 years at the University of Texas Southwestern Medical Center as a Professor of Pediatrics and Pharmacology as the Carl B and Florence E. King Distinguished Professor Pediatrics before working at the Cancer Institute of New Jersey.

During his career, Dr. Kamen has been a recipient of a Scholar Award from The Leukemia & Lymphoma Society, and other research grants including the Damon Runyon Walter Winchell Fellowship, Burroughs Wellcome Clinical Pharmacology Award and an American Cancer Society Clinical Research Professorship. He has authored approximately 250 manuscripts (papers and chapters) and is the current Editor-in-Chief of the *Journal of Pediatric Hematology Oncology*. Dr. Kamen's main laboratory interests are centered around folate and anti-folate metabolism, drug development, neurotoxicity from therapy and metronomic therapy for cancer. Dr. Kamen resides in Princeton Junction, New Jersey.

Marie T. Leithauser, MBA, MS

Marie Leithauser is Executive Director of Business Operations, Discovery and Exploratory Clinical Research, Research and Development, Bristol-Myers Squibb. Previously, Ms. Leithauser was a research administrator and Adjunct Professor for the Laboratory for Cancer Research at Rutgers, The State University. In addition, her past experience includes positions as Research Assistant at Vanderbilt University and Laboratory Manager/Research Assistant in the Department of Biochemistry at the Medical College of Wisconsin. Ms. Leithauser earned her Masters of Business Administration from the University of Wisconsin-Milwaukee and a Masters of Science degree in Oncology from the University of Wisconsin-Madison. She resides in Lambertville, New Jersey.

Christina G. Tan, MD, MPH

Dr. Tan is the State Epidemiologist with the New Jersey Department of Health and Senior Services (NJDHSS). She oversees NJDHSS's Communicable Disease Service and Cancer Epidemiology Services, and serves as an ex-officio member of the New Jersey Commission on Cancer Research.

Dr. Tan graduated from Princeton University, the Mount Sinai School of Medicine, and the Johns Hopkins Bloomberg School of Public Health. She completed a residency in Internal Medicine/Primary Care at New York University Medical Center where she holds an adjunct clinical assistant professor appointment, and she is board-certified in internal medicine. Dr. Tan was an Epidemic Intelligence Service Officer stationed at NJDHSS during 2000 to 2002 and has been with NJDHSS as the Medical Director of the Communicable Disease Service during 2002-2008 and Deputy State Epidemiologist during 2005-2008.

Jeffrey A. Warren, M.P.A.

Jeffrey Warren is a Senior Advisor to the National Pharmaceutical Council and a Principal with JR Market Strategies, Inc., a healthcare-consulting firm. Previously, Mr. Warren was responsible for Strategic Marketing and Media Relations for Pfizer Health Solutions. Earlier in his career, he served as Executive Vice President, Corporate Development for Cathedral Healthcare System. During his tenure with Cathedral, Mr. Warren was a National Program Director for the Robert Wood Johnson Foundation's New Jersey Health Services Development Program. Warren's past experience includes a tenure as Vice President, Corporate Development with Hackensack Medical Center and serving as the first Executive Secretary of the New Jersey Hospital Rate Setting Commission. He is on the board of the Adler Aphasia Center and is on the board of the Institute for Medication Access and Compliance. Mr. Warren serves on the Editorial Task Force Committee of AMGA's "Group Practice Journal". Jeff has a Masters Degree (MPA) in Health Policy, Planning and Administration from the Wagner School of Public Service at NYU. He resides in Parsippany, New Jersey.

Outgoing Commissioners

The New Jersey Commission on Cancer Research extends its gratitude for the service of outgoing Commissioners Drs. Eddy A. Bresnitz, Harvey L. Ozer, and Barbara Rabinowitz. Their strong dedication and unwavering advocacy for cancer researchers and survivors will be sorely missed.

Eddy A. Bresnitz, M.D., MS (DHSS and NJCCR from 1999-2008)

Eddy A. Bresnitz, M.D., MS is an internist and preventive medicine physician and served as the Deputy Commissioner for the Public Health Services Branch in the New Jersey Department of Health and Senior Services. Dr. Bresnitz joined the Department as Assistant Commissioner/State Epidemiologist in 1999 and became Senior Assistant Commissioner in 2003 and Deputy Commissioner in 2005 until retiring from State Government in 2008. In his role as Deputy Commissioner/State Epidemiologist, Dr. Bresnitz oversaw the Divisions of HIV/AIDS Services, Family Health Services, Public Health and Environmental Laboratories, and Epidemiology, Environmental and Occupational Health Services. The Branch included the Cancer Epidemiology Service, the Office of Cancer Control and Prevention, the Comprehensive Tobacco Control Program and New Jersey CEED program.

Dr. Bresnitz received his M.D. degree in 1974 from McGill University in Montreal, followed by an internship and residency in internal medicine at Montefiore Hospital in New York City. He completed fellowships in pulmonary medicine and clinical epidemiology in the early 1980s at the University of Pennsylvania, where he also received an MS in clinical epidemiology. Prior to joining the Department of Health and Senior Services, Dr. Bresnitz was Professor and Chairman of the Department of Community and Preventive Medicine at the MCP Hahnemann (now Drexel University) School of Medicine in Philadelphia. Dr. Bresnitz served as President of the Council of State and Territorial Epidemiologists in 2007-2008 and is now the Medical Director, Adult Vaccines, Medical Affairs and Policy, Merck Vaccines and Infectious Diseases based in West Point, PA.

Harvey L. Ozer, M.D. (Served the NJCCR since 2005)

Dr. Ozer is Director of Research of the New Jersey Medical School (NJMS)-University Hospital Cancer Center of University of Medicine and Dentistry of New Jersey in Newark. He previously served at NJMS as Chairman of the Department of Microbiology and Molecular Genetics, where he remains Professor, and as Senior Associate Dean for Research. His research on molecular mechanisms of carcinogenesis and of aging has been continuously funded by the National Institutes of Health for over 30 years. An internationally recognized expert on molecular genetics and cell biology of DNA tumor viruses and their cell

2008 Commission Members and Staff

COMMISSION STAFF:

Ann Marie Hill
Executive Director

Michael C. Toleno
Assistant Director

Thomas Eldershaw
Grant Coordinator

Karen Schaefer
Secretarial Assistant

COMMISSION OFFICES:

New Jersey
Commission on
Cancer Research

PO Box 369
Trenton, NJ 08625-0369

PHONE
609-631-4747

FAX
609-588-3441

EMAIL
NJCCR@doh.state.nj.us

WEBSITE
www.njccr.com

interactions, Dr. Ozer has served on multiple National Institutes of Health and foundation training and research review panels as well as on editorial boards of scientific journals and on advisory committees to academic programs. He received his M.D. and initial research training at Stanford Medical School. Dr. Ozer resides in Hoboken, New Jersey.

Barbara Rabinowitz, Ph.D. **(Served the NJCCR since 1995)**

Dr. Rabinowitz was the first Commission member with expertise in the psychological and psychosocial aspects of cancer. She completed her doctorate in Social Work at Rutgers University and is also a registered nurse. Dr. Rabinowitz has published chapters in textbooks for physicians on the psychosocial aspects of cancer care as well as numerous articles on this and related topics. She has completed two important cancer research projects and is a frequent invited presenter for professional organizations nationwide. She is also the recipient of the National American Cancer Society St. George Award for leadership and the National Consortium of Breast Centers Inspiration Award. Dr. Rabinowitz retired in 2009 as the Director of Oncology Services for Meridian Health moving to North Carolina, establishing a consulting firm, Creative Solutions and is re-establishing her private practice in psychotherapy and sex therapy there as well.

This report of the New Jersey Commission on Cancer Research's major activities for the year 2008 is only a partial overview of the high quality work that is carried out every day in New Jersey in support of our mission.

NJ Association for Biomedical Research Awards NJCCR Chairperson

Anna Marie Skalka, Ph.D., Senior Vice President for Basic Research at the Fox Chase Cancer Center in Philadelphia was one of twelve *Outstanding Women of Science* recognized by the New Jersey Association for Biomedical Research (NJABR) at their 2008 Red Carpet Gala, held May 1, 2008, at Bridgewater Manor in Bridgewater, NJ. Dr. Skalka chairs the New Jersey Commission on Cancer Research. She is internationally recognized for her contributions to the understanding of the biochemical mechanisms underlying the replication of certain types of viruses called retroviruses.



According to NJABR Past-President Jayne Mackta, NJABR chose to recognize the accomplishments of women in science because too many “glass ceilings” still exist. “Speaking for a community concerned with improving the health and well-being of people and animals,” she says, “we have a vested interest in conquering what we describe as the glass ceiling ‘syndrome,’ hidden attitudes and biases that impact both women and minorities on the job. The American scientific community needs all the good people it can get, and, in an increasingly competitive global economy, we must demand gender-and color-blindness if we hope to succeed.”

In reflecting on the accomplishments of the honorees, Ms. Mackta noted, “Each of our honorees is a leader and has made significant contributions to her specific area of expertise. She has found ways to balance the demands of work and home. We will never know how fast each woman has had to run to stay on track. Nor can we calculate the cost of success—in personal and professional terms. What we do know is that our lives and society as a whole have been enriched by their dedication and hard work.”

2008 Annual Retreat on Cancer Research

The Annual Retreat on Cancer Research was held on May 28, 2008 at the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School in Piscataway. 2008 marked the tenth year that the New Jersey Commission on Cancer Research (NJCCR) and The Cancer Institute of New Jersey (CINJ) have collaborated on the Retreat.

The purpose of the Retreat is to promote interaction among investigators, provide a forum for the presentation of original research, aid in career development and

2008 – The Year's Highlights

One mark of its success is the fact that the Annual Retreat on Cancer Research has brought together over 5000 students since 1998.

training through presented lectures and focus groups, and increase awareness of the resources available within New Jersey. Since 1998, the Retreat has brought together over 5000 students, and hundreds of research faculty, physicians, nurses, patients, and advocates.

Each year the retreat has included presentations by invited world-renowned researchers specifically chosen for their scientific accomplishments. **Dr. C. David Allis**, Joy and Jack Fishman Professor and Head of the Laboratory of Chromatin Biology at the Rockefeller University in New York, provided the morning keynote address on “Beyond the Double Helix: Writing and Reading the Histone Code.” The afternoon address featured **Dr. Arnold J. Levine**, Professor of Pediatrics and Biochemistry, The Cancer Institute of New Jersey/UMDNJ-Robert Wood Johnson Medical School, and Professor, Simons Center for Systems Biology, Institute for Advanced Study, whose talk was entitled “Single Nucleotide Polymorphisms in the p53 Pathway.”

A highlight of the retreat was the public forum, which focused on the unmet needs of cancer survivors. Long-term survivorship of cancer is now a reality for millions of Americans. Meeting the complex medical, psychological, social, and spiritual needs of this growing population presents a significant challenge. The NJCCR, along with the CINJ, developed this forum to meet the needs of this group and also to challenge New Jersey researchers and allied health care professionals to develop and implement new strategies to address these needs.



Panel members participate in the Public Forum at the 2008 Annual Retreat on Cancer Research

DonnaLyn Giegerich, MBA, CIC, RYT, began the public forum with an inspirational and motivational discussion of her battle with cancer entitled “A Call to Wellness.” Following Ms. Giegerich’s presentation, audience members interacted with the following panel members to discuss some of the complex issues common to survivors battling this disease: **Regina Cunningham, PhD, RN**, The Cancer Institute of New Jersey, **Kathleen Neville, PhD**, Kean University, **Lynne Kolton Schneider, PhD**, Private Sexuality Counselor/Therapist, **Kava Schafer, MDiv, MA**, University of Pennsylvania, **Barbara Hoffman, JD**, National Coalition on Cancer Survivorship, and **Barbara Rabinowitz, PhD**, Meridian Health System and former commissioner of the NJCCR. The public forum

can be viewed at <http://rwjms.umdnj.edu/itunesu>.

Poster sessions were held throughout the day featuring the latest cancer research being conducted in New Jersey. Each year, graduate and postdoctoral students compete for the NJ Cancer Research Awards for Scientific Excellence. Below are the winners of the awards, which are sponsored by Johnson & Johnson pharmaceutical company:

1. **Chun Chu**, UMDNJ – Robert Wood Johnson Medical School - CABM, for “Apoptosis and Autophagy Induction in Mammalian Cells by RNA Knockdown of mRNA Capping Enzymes”

2. **Sylvain Gaillard**, UMDNJ – New Jersey Medical School, for “Metrology of Propagation of the – Particle-Induced Bystander Effect: The Role of Nuclear Traversal and Gap-Junction Communication”
3. **Vasudeva Ginjala**, UMDNJ – Robert Wood Johnson Medical School/CINJ, for “Polycomb Group Members BMI-1, CBX2 and EZH2 are Recruited to Sites of DNA Damage”
4. **Huiqing Liu**, Rutgers, The State University, for “A Procedure to Identify mRNA Gene Targets in Human Kidney Cancer”
5. **Karl Miletti-Gonzalez**, UMDNJ- Robert Wood Johnson Medical School/CINJ, for “Regulation of Matrix Metalloproteinase-9 (MMP-9) Expression by CD44S in Breast Carcinoma Cells Involves Presenilin 1/Gamma-Secretase Activity”
6. **Kevin Nikitezuk**, UMDNJ- Robert Wood Johnson Medical School/CINJ, for “An Engineered Vaccine Delivery System for Immune System Modulation”
7. **Erin O’Hea**, Cooper University Hospital, for “Racial Differences in Predictors of White, Black, and Latino Women’s Intentions to Adhere to Breast Cancer Screening Recommendations”
8. **Brij Patel**, Rutgers, The State University of New Jersey, for “Inhibition of PARP Sensitizes Cells to Yondelis”
9. **Liangping Peng**, UMDNJ- New Jersey Medical School, for “The Role of PHF10 in Cellular Senescence”
10. **Sarah Pfau**, Princeton University, for “Toward a High Content RNA Screen to Identify Regulation of Mammalian Quiescence”
11. **Jia Shi**, UMDNJ- Robert Wood Johnson Medical School/CINJ, for “Coordinated Regulation of Alternative Splicing of WNT/,-Catenin Pathway Genes by Caffeine”

White Beeches Sponsors Annual Benefit Event to Aid Cancer Research

On June 17, 2008 the Ladies of White Beeches hosted the 13th Annual Benefit Event, “Dreams of Hopes and Cures.” Thanks to the generosity of the White Beeches members, their guests and supporters of this event, more than \$33,000 was raised. These funds will support additional cancer research projects in New Jersey.

One of the guest speakers at the event was Ms. Kerri-Ann Norton, a researcher in the Computational Biology and Molecular Biophysics Program at Rutgers University. Ms. Norton is a recipient of one of the fellowships made possible through the White Beeches’ fundraising efforts. Ms. Norton is one of the more talented researchers in the state. She is currently working on a model of breast cancer progression.

2008 – The Year's Highlights



In just 13 years, White Beeches benefit events have provided over \$230,000 for cancer research projects in New Jersey and have helped to generate more than \$6.5 million for cancer research in the State.

Since additional funding for cancer research is always needed to support the many deserving and promising programs in New Jersey, the NJCCR is fortunate and grateful to be the beneficiary of the White Beeches Annual Benefit event.

The New Jersey Breast and Prostate Cancer Research Funds

The NJCCR administers the New Jersey Breast Cancer Research Fund (BCRF) and the Prostate Cancer Research Fund (PCRF). The BCRF and PCRF are funded by private contributions, special project revenues, and check-off boxes on the New Jersey State Income Tax Return. The income tax check-off box allows citizens to voluntarily contribute a portion of their income tax refund or payment. In 2007, the BCRF raised over \$255,000 for breast cancer research while the newer PCRF generated over \$23,000.



Through its competitive scientific peer review process and combined with private donations and other special project revenues, the NJCCR funds worthy research projects investigating the causes, prevention, screening, treatment or cure of breast or prostate cancer. Funds may also be awarded to support basic, behavioral, clinical, demographical, epidemiological and psychosocial research as well as educational programs.

Conquer Cancer License Plate

The “Conquer Cancer” specialty license plate brings the fight against cancer to the streets of New Jersey. Since 1998, over 54,000 license plates have been sold and more than \$4 million dollars have been raised for cancer research in the state.



One hundred percent of the license plate proceeds that the NJCCR receives are used to fund talented scientists at New Jersey research institutions. In 2008, over 2,500 “Conquer Cancer” license plates were sold. When the proceeds are combined with license plate renewal fees, more than \$430,000 was raised for cancer research.

New Jersey motorists can purchase the “Conquer Cancer” license plate at all Motor Vehicle Commission offices or through its website (www.accessdmv.com) at any time during the registration cycle. The initial cost is \$50, with a \$10 annual renewal fee.

The grant and fellowship program is the central feature of the New Jersey Commission on Cancer Research (NJCCR). Our mission is to achieve a

better understanding of the causes, detection, cure, and prevention of cancer. The year 2008 marks 25 years of funding high quality research by innovative young scientists and established investigators embarking on new avenues of research in their careers. Over this time period, more than 760 investigators have received support from the NJCCR. These investigators have published hundreds of scientific articles unraveling the mysteries of the disease process. These same investigators have subsequently secured more than \$350 million in federal financial support as well as support from other national funding agencies.

The biggest challenge in 2008 was selecting 27 projects for funding from the 70 applications that were submitted. Our Scientific Review Panel of out-of-state experts in cancer research spent long hours reviewing the applications. They recommended the most worthwhile in terms of creative insight, innovative approach, and prospects for success. The majority of the grant recipients selected by the NJCCR Commissioners are in the critical early years of their careers. Financial support for these scientists is essential to their ability to obtain the data necessary to successfully compete for larger awards from the National Institutes of Health and other national funding organizations. By identifying and funding the most gifted and talented young investigators, NJCCR's investment pays future dividends to New Jersey through additional funding to the state's research institutions. Due to financial limitations, there are always more applications worthy of funding than we are able to support. Nevertheless, by focusing our support on the most promising projects, we are able to have a positive impact on cancer research in NJ.

The NJCCR is proud of its record of accomplishment over the last quarter of a century, but is even more excited about the future opportunities. For example, the FY2009 budget appropriates \$5 million for cancer research, a 5-fold increase over the FY2008 budget. With this increase in funding, our Commissioners, dedicated staff, and supporters plan on accomplishing even more in the next 25 years.

A NJCCR Success Story

One of the NJCCR's goals is to facilitate the transition of talented postdoctoral research fellows to permanent faculty members. Dr. Vassiliki Karantza-Wadsworth was a 2007 NJCCR grant recipient. In 2008 Dr. Karantza-Wadsworth received the Howard Temin Pathway to Independence in Cancer Research Award from the National Cancer Institute and is now a medical oncologist at The Cancer Institute of New Jersey and an Assistant Professor of Medicine at the University of Medicine and Dentistry's Robert Wood Johnson Medical School. Dr. Karantza-Wadsworth is an example of how the NJCCR system of supporting gifted and talented young investigators works.



2008 Research Highlights

BREAST CANCER RESEARCH FUND

Gyan V. Bhanot, Ph.D., Rutgers, The State University of New Jersey
RT-PCR Assay for Breast Cancer Subtypes
\$132,000

TWO YEAR AWARDS

Victor T. Chang, M.D., Veterans Biomedical Research Institute
Comorbidity and Survival in Patients with Advanced Cancer
\$113,684

Lawrence E. Harrison, M.D., UMDNJ-New Jersey Medical School
In Vivo Thermal Sensitization of Intraperitoneal Chemotherapy
\$132,000

Utz Herbig, Ph.D., UMDNJ-New Jersey Medical School
Tumor Suppression by Telomere Dysfunction Induced Senescence
\$130,900

Kim M. Hirshfield, M.D., Ph.D., UMDNJ-Cancer Institute of New Jersey
Epithelial Integrity and Breast Cancer Recurrence
\$132,000

Melissa B. Rogers, Ph.D., UMDNJ-New Jersey Medical School
Mycoplasma and BMP2 in Lung Cell Transformation
\$130,900

Roger Strair, M.D., Ph.D., UMDNJ-Cancer Institute of New Jersey
A Pilot Study of Nuclear Factor kappa-B Inhibition
\$132,000

Renping Zhou, Ph.D., Rutgers, The State University of New Jersey
Novel Regulation of Skin Carcinogenesis by Ephrin-A5 and EphA2
\$132,000

PROSTATE CANCER RESEARCH FUND

Anant Madabhushi, Ph.D., Rutgers, The State University of New Jersey
Computerized Detection and Grading of Prostate Cancer Histology
\$66,000

ONE YEAR AWARDS

Shridar Ganesan, M.D., Ph.D., UMDNJ-New Jersey Medical School
Immune Infiltrates in HER2+ breast cancer
\$57,130

Isaac Yi Kim, M.D., Ph.D., UMDNJ-Cancer Institute of New Jersey
BMP-6 and Neuroendocrine Differentiation in Prostate Cancer
\$52,800

Pranela Rameshwar, Ph.D., UMDNJ-New Jersey Medical School
Mesenchymal Stem Cell as Cancer Target in Bone Marrow
\$66,000

Janine H. Santos, Ph.D., UMDNJ-New Jersey Medical School
Mitochondrial Telomerase and its Impact in Prostate Cancer
\$49,500

NOTE:

Dr. Madabhushi has published or presented eighteen conference papers, seven abstracts, and three research journal articles describing research achieved during the current grant cycle. In addition, one provisional and one full patent application were also filed by Dr. Madabhushi during this period.



Since 1988, the NJCCR has helped to attract and retain promising scholars pursuing careers in cancer research through its successful fellowship program.

Attracting a core of outstanding scientists to our research institutions in New Jersey not only brings in additional funding from other sources, it attracts promising investigators. Jobs are created, our technological base is enhanced, and the quality of science education is improved. As promising students come to New Jersey for their training, a continual source of scientists is also available for the pharmaceutical and biotechnology industries when these students graduate.

Over the years, the fellowship program has proven to be a sound and promising investment that has helped establish the foundation for the kind of scientific investigation that will keep New Jersey at the forefront in the war against cancer.

HIGHLIGHTS OF PROGRAM'S SUCCESS

- Sixty nine percent (69%) of postdoctoral fellows found academic or industry research positions within 4 years of award.
- Eighty five percent (85%) published at least two scientific articles per study.
- One hundred percent (100%) of sponsors rated the usefulness of the fellowship program as extremely or very useful to the development of their laboratories.
- Sixty one percent (61%) of the fellows contributed to the laboratory's capacity to attract national funding from \$1.7 to \$3.5 million.

POST DOCTORAL FELLOWSHIPS

Christine M. O'Connor, Princeton University
Deciphering the Functions of the HCMV encoded GPCR
\$72,000

James Monaco, Rutgers, The State University
Detecting Pre-malignant Prostate Lesions using MRI
\$72,000

PRE DOCTORAL FELLOWSHIPS

Kevin F. Anton, UMDNJ-Robert Wood Johnson Medical School
Role of Macrophages in Tumor Growth
\$45,000

Ethan Fitzpatrick, UMDNJ-New Jersey Medical School
Regulation of GTPase Signaling by Sec 14p Domains
\$45,000

Erin M. Haley, Princeton University
A Role for Autophagy in Prostate Cancer Stem Cells
\$45,000

Jean S. McGee, Princeton University
Rif1p in Preferential Elongation of Short Telomere
\$45,000

Kevin P. Nikitzuk, Rutgers, The State University
Immune Targeting Engineered Vaccine Delivery System
\$45,000

Fellowship Benefits

- Enhances ability to begin new research direction.
- Results in new discovery or significant findings.
- Supports ability to attract national funding.
- Supervises training of graduate and undergraduate students.

Fellowships: A Commitment to the Future

Fellowships: A Commitment to the Future

Erin P. O'Keefe, Princeton University
Cellular Proteins in HCMV Induced Cell Cycle Alteration
\$45,000

Jay H. Oza, UMDNJ-Robert Wood Johnson Medical School
The Effect of Poly (ADP-Ribose) Polymerase (PARP)
\$45,000

Erica Salerno, UMDNJ-New Jersey Medical School
The Role of miRNAs and Cancer Stem Cells in CLL
\$45,000

Nilay Sethi, Princeton University
Involvement of Notch Pathway in Cancer Metastasis
\$45,000

Christopher E. Slagle, Princeton University
The Role of FoxH1 During Metastasis
\$45,000

Alexandra Terskiy, UMDNJ-New Jersey Medical School
Multiple Myeloma Cell Growth Inhibition by an Opioid
\$45,000

Benjamin J. Tiede, Princeton University
The Role of Mammary Stem Cells in Carcinogenesis
\$45,000

SUMMER FELLOWSHIP (\$4,000 each)

Jeremy Amon, Princeton University

Pinxia Chen, UMDNJ-The Cancer Institute of New Jersey

Walter Chen, Princeton University

YongJie Chen, UMDNJ-The Cancer Institute of New Jersey

Lindsay D'Annunzio, Rutgers, The State University

Caitlin Fay, Princeton University

Lee Fisher, Princeton University

Zhama Hakhverdyan, Rutgers, The State University

Eric LaBouff, Rutgers, The State University

Susan Lee, UMDNJ-The Cancer Institute of New Jersey

Miho Maeda, Rutgers, The State University

Saqib Malik, Rutgers, The State University

Joseph Maffei, Rutgers, The State University

Rohan Mathur, Rutgers, The State University

Karen McMurdie, Drew University

Monai Mehta, Rutgers, The State University

Amanda Mei, Rutgers, The State University

Euphemia Mu, Princeton University

Kupa Mutunga, Princeton University

Jay Naik, Rutgers, The State University

Vanessa Palka, Rutgers, The State University

Michael Patel, UMDNJ-The Cancer Institute of New Jersey

Robert Toth, Rutgers, The State University

Matthew Zegarek, Rutgers, The State University



Funding

Cancer Research Fund	\$1,000,000
FY07/08 Second Year Award Funding & Carryover	1,089,841
Conquer Cancer License Plate	437,799
Breast Cancer Research Fund	255,985
Prostate Cancer Research Fund	23,240
Gifts, bequests, donations, grants	65,545
Total Revenues	\$2,872,410

Expenses

FY08 First Year Award Funding	
Grants, Fellowship, Meetings/Programs	\$1,575,676
FY08/09 Second Year Award Funding/Carryover	513,157
FY07/08 Second Year Award Funding/Carryover	493,500
Research management & support	290,077
Total Expenditures	\$2,872,410

Monies raised through the Breast Cancer Research Fund, Prostate Cancer Research Fund, and the Conquer Cancer License Plate or from contributions, do not finance the Commission's operating expenses. 100% of these contributions go directly to an approved cancer research project in New Jersey and are tax deductible.

Furthermore, what this information does not show, is the value of the tremendous amount of volunteer time that goes into these activities – the human element that makes the work of the New Jersey Commission on Cancer Research (NJCCR) possible. On behalf of the NJCCR, we would like to thank everyone who has contributed time or money towards the fight against cancer.



“ In life we shall find many men that are great, and some that are good, but very few men that are both great and good.”

It is with deep sadness that the NJCCR reports that New Jersey has lost one of its most dedicated and talented volunteers in Peter Doherty. This short tribute is meant to honor the many ways Peter made a difference.

If you have a “Conquer Cancer” license plate on your car, you have Peter to thank. He created, designed, and promoted this “first of its kind” specialty license plate dedicated to supporting cancer research in New Jersey. Since 1998, the license plate has raised more than \$4,000,000 for more than 75 cancer research projects here in New Jersey. Peter Doherty literally took the fight against cancer to the streets of New Jersey.

Peter also helped thousands of men deal with prostate cancer. He helped create and lead the Morristown Prostate Support Group, one of the largest support groups in the country. He was a founding member of the Prostate Cancer Coalition of New Jersey and worked on numerous programs and seminars aimed at helping to educate men with prostate cancer. He recently was awarded the Harry Pinchot Award for extraordinary service to others in the prostate cancer community.



Carolyn and Peter Doherty celebrate the opening of the Peter B. Doherty Men’s Cancer Center at Morristown Memorial Hospital (MMH) in 2005. Picture provided by MMH.

Peter was a mentor, sage and, most importantly, a dear friend to us at the NJCCR. Peter was that special person who brought out the best in all of us...we worked harder, dug deeper and reached farther because of him. He was not only a great person but a truly *good* man. We will miss you Peter, but you will always be a part of us.

He is survived by his devoted wife of 47 years, Carolyn Putits Doherty.

Celebrating the Life of Peter Doherty



CELEBRATING
25 Years of
Excellence



Results Through Research



*Returning \$10 to
New Jersey for Every
Research \$1 Awarded*



**Jon S. Corzine
Governor**